Matrix-bound Nanovesicles as an Extracellular Source of Lysyl Oxidase by Lee, Yoojin
 
  
Title Page  











Yoojin Cadence Lee 
 











Submitted to the Graduate Faculty of the 
 
Swanson School of Engineering in partial fulfillment 
  
of the requirements for the degree of 
 














Committee Page  
UNIVERSITY OF PITTSBURGH 
 















Yoojin Cadence Lee 
 
 
It was defended on 
 
July 14, 2020 
 
and approved by 
 
Dr. Lance Davidson, Ph.D. Professor 
Department of Bioengineering 
 
Dr. George Hussey, Ph.D., Research Assistant Professor 
Department of Surgery 
 
Dr. Savio L-Y. Woo, Ph.D., D.Sc., D.Eng. Distinguished University Professor Emeritus 
Department of Bioengineering 
 
Dr. Urszula Zdanowicz, M.D., Carolina Medical Center, Warsaw, Poland 
 
Dissertation Director: Dr. Stephen F. Badylak, D.V.M., Ph.D., M.D., Professor 


































Matrix-bound Nanovesicles as an Extracellular Source of Lysyl Oxidase 
 
Yoojin Cadence Lee, Ph.D. 
 
University of Pittsburgh, 2020 
 
 
Biologic scaffolds produced from extracellular matrix (ECM) have been commonly 
implemented as inductive templates for constructive tissue remodeling in multiple musculoskeletal 
sites. The discovery of matrix-bound nanovesicles (MBV), a unique subpopulation of extracellular 
vesicles embedded within the ECM, has prompted the further study of MBV structure, internal 
cargo, and overall function. MBV are more specifically defined as lipid-bound extracellular 
vesicles that possess the ability to modulate cell behavior as a function of their internal cargo of 
biologically active signaling molecules (e.g., microRNAs, proteins, lipids, cytokines). The lipid 
membrane of MBV is decorated with a variety of surface proteins that are unique to the local 
function and anatomic location from which MBV are harvested.  
Lysyl oxidase (LOX) is an enzyme responsible for catalyzing collagen cross-linking and 
serves an essential role in tissue stabilization. In this dissertation, LOX is investigated because of 
its function of regulating cross-linking of collagen in tissues and its potential to be implemented 
as a therapy in damaged or healing tissues that lack sufficient cross-linking. There are substantial 
challenges associated with isolating and purifying LOX in high quantities, which limits full 
characterization and understanding of the protein. Herein, MBV is isolated from multiple tissue 
types in abundance and is presented as a promising method of isolating LOX. 
The objectives of the present dissertation were to isolate MBV-associated LOX from ECM 
bioscaffolds and to determine its effects on the development of collagen fibrils in vitro. ECM 
bioscaffolds were solubilized using enzymatic digestion with collagenase and elastase, and 
incubation in a high salt solution. Results show that MBV-associated LOX in the ECM is present 
 v 
in its 52 kDa pro-peptide form and that it is enzymatically active when isolated with elastase 
digestion. MBV-associated LOX activity significantly decreases when treated with LOX inhibitor 
β-aminopropionitrile (BAPN) or when proteinase K is utilized to remove surface proteins. 
Furthermore, MBV-associated LOX enhances the formation of cross-linked collagen and the 
strength collagen constructs in vitro. MBV offer an attractive method to deliver surface-associated 
LOX, which through its direct role in collagen cross-linking and matrix regulation for enhancing 
the biomechanics of remodeled tissue, specifically its strength.  
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1.0 Introduction 
1.1 Cross-Linking of Collagen for Tissue Integrity and Stabilization 
Collagen is the most abundant insoluble protein in the extracellular matrix (ECM) and in 
connective tissues. The network of collagen is formed largely by cell-mediated self-assembly of 
small collagen molecules and is essential in providing strength to tissues where mechanical 
function is essential (e.g., skin, cartilage, tendon). The synthesis of collagen begins primarily in 
fibroblast cells that facilitate the process of transcription and translation of the collagen genes. 
Collagen chains, known as procollagen, are transported to the endoplasmic reticulum (ER) for 
post-translational modifications including hydroxylation, glycosylation, and formation of disulfide 
bonds [1]. Once in the triple helical formation, the procollagen molecules are sorted in the Golgi 
apparatus, assembled into secretary vesicles, and released into the extracellular space. The 
procollagen molecules are then cleaved by peptidases and collagen monomers to form stacking 
units, also known as collagen fibrils [2, 3].  
The assembly of collagen fibrils in the extracellular space is an orchestrated process that 
dictates the stability of the covalently bonded supramolecules. Collagen fibrils are stabilized by 
cross-links that are driven most notably by the enzyme lysyl oxidase (LOX) [4]. LOX is essential 
in catalyzing the reaction that forms the covalent bonds between triple helical collagen fibers, 
which subsequently stabilize the ECM. The dynamic microenvironment of the ECM influences 
various cellular processes such as proliferation, differentiation, adhesion, and migration; these 
processes in turn contribute to maintaining tissue and organ homeostasis [5]. Collagen cross-links 
are also important in the mechanical properties of tissues during development [6]. The strength 
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and biomechanical properties of the ECM are dependent on proper formation of such 
intermolecular collagen cross-links, which when gone awry, can dictate the onset or progression 
of pathologies associated with connective tissues.  
1.2 Lysyl Oxidase and its Role in the ECM  
1.2.1 The Enzymatic Role and Function of LOX  
Numerous studies have reported the role of LOX in the ECM during remodeling events 
and fibrillogenesis in various tissues [7, 8]. Although LOX has been classically characterized as 
an extracellular enzyme, emerging studies also show that LOX has intracellular biological roles 
[9, 10]. LOX has been reported to be involved in development [11], tissue remodeling [12], fibrosis 
[13, 14], and neoplasia [15-17], which all elucidate the importance of LOX as a key player in a 
variety of biological events.  The present dissertation focuses on the extracellular role in of LOX 
and its essential function of mediating collagen cross-linking in the ECM.   
 LOX is dependent on Cu2+ molecules to enzymatically catalyze the cross-linking of 
collagen and elastin that is essential for the structural integrity and function of connective tissues 
[18]. The covalent cross-links are formed by oxidative deamination of lysine and hydroxylysine 
residues to form allysines in the telopeptide domains of collagen molecules [19]. Malfunction and 
dysregulation of LOX proteins can lead to diseases associated with abnormal collagen fibrils and 
disruption in fibrillogenesis. Such diseases include lathrysm from the inhibition of LOX [20], 
Ehlers Danlos syndrome [7], and dilated cardiomyopathy [21].  LOX is essential in reinforcing 
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and stabilizing collagen fibers and can affect the tensile strength of connective tissues including 
tendon, bone, and skin, and the ECM.   
In mammals, LOX exists in a family of proteins that includes 5 isoforms: LOX, and LOX-
like 1-4 (LOXL1-4). These isoforms have >50% sequence homology within their catalytic domain 
in the carboxy terminus [22], which consists of a cytokine receptor-like (CRL) domain, copper-
binding motif, and a lysyl-tyrosyl-quinone (LTQ) cofactor [23, 24]. The amine terminus of the 
LOX isoforms is more variable and likely important for protein-protein interactions, substrate 
specificity, and function. Of the five isoforms, LOX and LOXL1 are often paired together for their 
similar protein structure and presence of pro-domains, which enable their secretion as proenzymes 
and extracellular processing by procollagen C-proteinases [25]. Such processing has been shown 
to require the pro-domains of LOX and LOXL1, which allows for substrate recognition for 
directing the enzymes to elastic fibers that interact with tropoelastin [26].  On the other hand, 
LOXL2, LOXL3, and LOXL4 contain four scavenger receptor cysteine-rich (SRCR) domains that 
are not present in the other isoforms. The functions of the SRCR domains are not clear, but may 
be important for protein-protein interactions [27]. The differences of the LOX isoforms may 
account for their biological functions and mechanism of associating with ECM.   The present 
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2.0 The ECM and its Use as a Biologic Scaffold 
The ECM is a complex, tissue-specific three-dimensional network defined by the structural 
and functional components secreted by all cells of tissues [28]. Such secreted products include 
proteins, polysaccharides, enzymes, and carbohydrates, which all work to form the intricate 
network of the ECM. The ECM consists primarily of collagens but also contains growth factors, 
glycoproteins (laminin, fibronectin), proteoglycans, and glycosaminoglycans (GAGs) that are 
unique to each tissue type and enable tissue-specific roles and functions. The microenvironment 
of the ECM is highly dynamic, and the maintenance of normal physiology and function is largely 
dependent on the interaction between the ECM and cells. This concept of bidirectional cross-talk 
between cells and the surrounding ECM has been described as dynamic reciprocity [29], where 
the ECM can dictate and influence cell behavior and phenotype [30], which in turn influences the 
cellular responses to environmental stressors and remodeling events of the ECM.   
Understanding the full complex composition and diverse functions of the ECM is an 
ongoing investigation by researchers today. One of the primary uses of ECM in the field of tissue 
engineering and regenerative medicine is as a biologic scaffold material. Since the 1940s, scientists 
have investigated the application of ECM as a biologic scaffold by decellularization. Because the 
ECM is designed and manufactured by resident cells, it is not only biocompatible but provides the 
ideal environment when used as a biologic scaffold [31].  
The first report of a crude decellularization process was in 1948 by William E. Poel, where 
muscle tissue was completely pulverized at -70°C [32]. Decellularization strategies and techniques 
have evolved since Poel’s study and have allowed for the beneficial use of the ECM as 
bioscaffolds. Biologic scaffolds derived from mammalian ECM have been used successfully as 
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templates of inductive functional tissue remodeling in multiple anatomic sites including urinary 
bladder [33], ventral hernia [34], musculoskeletal tissues [35], dura mater [36], and tendon [37] to 
name a few. Advantageously, ECM bioscaffolds are not chemically cross-linked or highly 
cellularized, which leads to their rapid degradation and replacement with well-organized, site-
appropriate host tissue, in contrast to the innate mammalian wound healing response of scar tissue 
formation [31, 38]. The favorable outcomes of constructive remodeling associated with ECM 
bioscaffolds are due to scaffold degradation and release or exposure of matricryptic peptides [38], 
endogenous or stem cell recruitment [39], modulation of macrophage phenotype [40], as well as 
the exposure to matrix-bound nanovesicles (MBV) [41]. Such properties make ECM bioscaffolds 
and their molecular components an attractive tool for functional tissue repair and regenerative 
medicine applications. 
2.1 Matrix-Bound Nanovesicles in the ECM 
Extracellular vesicles (EVs), of which MBV are a unique type, are important mediators of 
cell-cell communication, sharing biological signals and transmitting information that influence 
biological processes [42]. The first identification of  EVs was in 1967 by Peter Wolf, where he 
observed EVs as subcellular coagulant material and named them “platelet dust” [43]. It is now 
clear that EVs are nano-packages of information that all cells release as a form of paracellular 
communication [44, 45]. The functions of EVs are incredibly diverse, playing different roles in 
regulating physiological and pathological functions including immune suppression, antigen 
presentation, tumor suppression, and transfer of signaling molecules to name a few [46-49].  
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The heterogeneity and variable composition of EVs make defining types of EVs 
challenging, but EVs can be classified in 3 major subgroups based on their size. The largest group 
includes apoptotic bodies that are a result of extensive membrane budding during apoptosis and 
range from 1 to 5 μm in diameter [50]. Microvesicles, released from the plasma membrane, are 
slightly smaller and range from 150 to 1,000 nm in diameter [51]. The smallest members of EVs, 
exosomes range from 30 to 100 nm in diameter [46]. Exosomes contain a cargo of cytosolic 
products including microRNA (miRNA), cytokines, and chemokines that can be internalized by 
cells and influence various physiologic and pathologic processes [52]. Despite their classification 
in the subgroups, all EVs are key players in paracellular communication and intercellular transfer 
of cargo.  
Matrix-bound nanovesicles (MBV) are a unique type of EVs, discovered firmly embedded 
within the ECM in contrast to liquid-phase EVs [41, 53]. EVs are secreted by most cell types into 
the extracellular space and are typically found in cell culture supernatants, blood, saliva, plasma, 
and cerebrospinal fluid [51, 54]. MBV are secreted by tissue-resident cells and integrated within 
the ECM, which delineates their biological roles as uniquely different from EVs found in 
biological fluids. It has been previously shown that MBV isolated from ECM bioscaffolds have 
not only unique differential miRNA signatures based on their anatomical tissue source [41], but 
also distinct phospholipid profiles [53].  MBV have been shown to modulate cell behavior as a 
function of their cargo of biologically active signaling molecules (e.g., miRNAs, proteins, lipids, 
cytokines), influence neuron differentiation, and promote a pro-remodeling macrophage 
phenotype [55-57]. More research is necessary to fully understand the mechanisms of biogenesis 
and integration of MBV into the fibrillar network of the ECM. One particular interest of study may 
be associated to the lipid membrane of the vesicles.  
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2.2 MBV-Associated Lysyl Oxidase 
As described above in chapter 1.2.1, lysyl oxidase (LOX) is a copper-dependent enzyme 
that catalyzes the cross-linking of the molecular units of collagen and elastin, which is an essential 
post-translational modification occurring in the biogenesis of collagenous connective tissues [18].  
However, full characterization and understanding of LOX’s catalytic activity remain unknown due 
to its highly insoluble properties and difficulties in obtaining large quantities of LOX [58]. In 
addition, procedures to isolate  LOX from tissue involve high concentrations of urea and extensive 
buffer changes [59, 60], which ultimately limits the quantity of LOX able to be isolated. Despite 
these obstacles, it has been demonstrated that LOX is essential for proper ECM development and 
stabilization of tissues [8, 61, 62]. 
Previously, studies have used LOX as a targeting approach to treating fibrosis by inhibiting 
its activity [63, 64]. However, methods of inhibiting LOX have associated adverse impacts. For 
example,  the use of β-aminopropionitrile (BAPN), an irreversible inhibitor of LOX, has the 
potential of producing toxic byproducts by interacting with other amine oxidases [65].  A copper 
chelator tetrathiomolybdate has also been utilized to inhibit LOX activity [66, 67], but its use is 
associated with potential toxicity from the inherent decrease of copper availability for normal 
physiologic processes [68, 69]. Therapeutic approaches using LOX has been explored but has been 
limited due to such challenges. MBV-associated LOX is a novel direction to implement the 
function of LOX as a cross-linking enzyme to strengthen and promote organized healing in 
musculoskeletal tissues. 
LOX has been identified in several proteomic analyses studies of ECM including Matrigel 
[70], synovium-derived stem cells [71], and ovine forestomach matrix [72]. It is well-established 
that biologic scaffolds composed of ECM promote constructive tissue remodeling and at least 
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partial restoration of function. Therefore, it is proposed that LOX, specifically when present in 
ECM, plays a positive role in tissue remodeling. The present dissertation reports an extracellular 
source of LOX associated to the ECM, specifically by MBV.  
2.3 Future Perspectives  
Much of the research today on EVs is largely focused on their potential as biomarkers of 
disease [73-75]. LOX antibodies for targeting disease have been reported in preclinical studies but 
lack sufficient data showing effectiveness in the extracellular environment [76]. More extensive 
research is necessary to implement LOX in clinical trials for therapeutic applications. Herein, LOX 
was discovered on the surface of MBV, which distinguishes its therapeutic potential from prior 
studies that are directed at targeting LOX’s activity, specifically. MBV-associated LOX can be 
obtained from tissue ECM and provides a novel approach to isolate LOX. Future studies are 
necessary to implement MBV-associated LOX for the therapeutic purpose of enhance the cross-
linking of damaged tissues, such as during overuse injuries like tendinopathy.  
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3.0 Objectives 
Extracellular vesicles (EVs) have been under intensive research in the past decade as a 
natural system for cellular communication and intracellular transfer of molecular cargo. Matrix-
bound nanovesicles (MBV) have been a recent biological discovery in the field of EVs. MBV exist 
embedded within extracellular matrix (ECM) bioscaffolds rather than fluid-based systems. MBV 
are similar to exosomes, a type of EV, in their nanometer size and containment of molecular cargo, 
but MBV are different in that they lack common exosomal surface markers including CD63, CD81, 
CD9, and HSP70 [41]. Rather, one of the early identified surface proteins identified with MBV is 
lysyl oxidase (LOX). MBV-associated LOX is easily isolated by solubilization of the ECM and 
ultracentrifugation, avoiding lengthy procedures of isolating LOX proteins, and it offers 
therapeutic potential in applications where cross-linking of the ECM is dysregulated. However, 
given that MBV are a relatively new finding, more research is required to understand the 
physiological roles as well as biogenesis of the vesicle and its associated proteins.  
The objectives of the present dissertation were to determine how LOX is associated 
with MBV and evaluate the biologic activity of MBV-associated LOX. MBV-associated LOX 
was identified in urinary bladder matrix ECM (UBM-ECM), small intestinal submucosa ECM 
(SIS-ECM), dermal ECM (dECM), and tendon ECM (tECM). MBV-associated LOX was 
identified on the surface of MBV by immunoprecipitation and immunolabeling experiments.  
MBV-associated LOX is in its 52 kDa pro-peptide form as assessed by Western blot analyses. In 
addition, MBV-associated LOX activity significantly decreases when treated with LOX inhibitor 
β-aminopropionitrile (BAPN) or when proteinase K is utilized to remove MBV surface proteins.  
Furthermore, MBV-associated LOX enhances the formation of cross-linked collagen and the 
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strength of in vitro collagen constructs. The discovery and investigation of MBV-associated LOX 
provide insights to the role of MBV in ECM regulation and offers an alternative pathway through 
which LOX is secreted into the extracellular space. 
The long-term goal of the present dissertation is to provide a feasible method of utilizing 
MBV-associated LOX as a therapeutic by taking advantage of LOX’s enzymatic function of cross-
linking collagen to strengthen and stabilize tissues. Such therapy could be implemented in 
musculotendinous tissues that are subject to overuse injuries and where the innate healing process 
is slow and inefficient. Herein, MBV-associated LOX was determined to be enzymatically active 
and have biologic effects by enhancing the development of in vitro collagen constructs. MBV-
associated LOX may be used to strengthen tendons and ligaments where the integrity of the ECM 
is compromised in the case overuse injuries. In addition, the therapeutic use of MBV-associated 
LOX can be further applied to other tissue diseases such as aortic aneurysms, pelvic organ 
prolapses, and cutaneous wounds. 
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4.0 Central Hypothesis and Specific Aims 
 
Central Hypothesis: Matrix-bound nanovesicles (MBV) are an extracellular source of LOX and 
can be used to implement the enzymatic function of lysyl oxidase (LOX) in regulation of collagen 
and the ECM. 
 
Specific Aim 1: Identification and characterization of LOX isoforms in MBV isolated from ECM 
bioscaffolds 
Subaim 1.1. Determine the amount of LOX in MBV isolated from urinary bladder matrix ECM 
(UBM-ECM), small intestinal submucosa ECM (SIS-ECM), dermis ECM (dECM), and tendon 
ECM (tECM) by Western blot and nanoparticle tracking analyses (NTA). 
Subaim 1.2. Quantification of LOX isolated from various ECM scaffolds by ELISA 
Corollary Hypothesis: MBV isolated from different ECM will have varying amounts of LOX due 
to source tissue specificity and function, which can be implemented for specific biologic 
applications. 
Corollary Rationale: Previous work has shown that MBV isolated from various ECM bioscaffolds 
have unique protein cargo signatures, surface markers, and phospholipid signatures [41, 53]. Given 
that the ECM is an architecture of complex mixture of proteins, proteoglycans, and 
glycosaminoglycans, it is plausible that MBV isolated from ECM bioscaffolds derived from 
anatomically distinct source tissue will have varying amounts of LOX associated to the surface of 
the vesicles.  
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Specific Aim 2: Determine the biologic activity of MBV-associated LOX  
Subaim 2.1.  Determine how LOX is associated with the surface of MBV 
Corollary Hypothesis: The extracellular processing of MBV-associated LOX, by BMP-1 and other 
binding partners, is required to proteolytically activate LOX on the surface of MBV, in which 
MBV then can be utilized to regulate collagen cross-linking to strengthen tissues. 
Corollary Rationale: Previous studies have shown that after LOX is secreted to the extracellular 
space, it is processed and activated by pro-collagen C-proteinase bone morphogenic protein-1 
(BMP-1) [77]. However, the full activation mechanism of LOX according to tissue specificity is 
not fully understood. Other proteins have recently been identified to be associated and play a role 
in the mechanism of activating LOX (i.e., fibronectin [78], periostin [79], and fibromodulin [80] 
to name a few, which may be important in getting MBV-associated LOX to activate and function. 
Identifying and understanding the proteolytic activation mechanism of MBV-associated LOX will 
guide to identifying cellular binding partners of LOX and analyzing for the presence or absence of 
the catalytic cross-linking activity. 
 
Specific Aim 3: Determine the effect of MBV isolated ECM on the mechanical properties of a 
grown collagen construct in vitro by measurement of mechanical strength 
Corollary Hypothesis: MBV treatment during in vitro tendon development can alter LOX activity, 
thereby changing mechanical properties and microstructural arrangement of fibers in the matrix 
by enhancing LOX-mediated collagen cross-linking. 
Corollary Rationale: It is important to determine if MBV can enhance the formation and strength 
of an grown collagen construct in vitro to implement the potential therapeutic uses of MBV-
associated LOX.  
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5.0 Solubilization of ECM by Various Enzymes and High Salt Solution to Isolate MBV 
5.1 Introduction 
 
In the past decade, extracellular vesicles (EVs) have become of increasing of interest for 
their important roles in physiology as well as intracellular communication.  EVs affect other cells 
by transfer of cargo containing biologically active molecules (e.g., miRNA, mRNA, proteins) and 
through surface receptors that influence processes including homeostasis, angiogenesis, and tumor 
metastasis. [81-85].  EVs are heterogeneous in size, ranging from 40-5000 nm in diameter, and 
they are secreted by all cell types into the local microenvironment [86].   EVs have been 
successfully isolated from a variety of fluids including cell culture medium, plasma, serum, saliva, 
breast milk, and urine [54, 87-89]. The most commonly used method to isolate EVs is differential 
centrifugation, which is comprised of numerous successive centrifugation and ultracentrifugation 
steps [90]. This technique allows particles heavier than the solvent to sediment after each 
centrifugation step. EVs remain in the supernatant after initial, relatively lower speed 
centrifugation, and is then able to be isolated with subsequent centrifugation with increased forces 
(ultracentrifugation) and longer duration. 
Matrix-bound nanovesicles (MBV) have been identified in ECM scaffolds and are a unique 
type of EV distinctly different from those found in biological fluids. After disruption of the ECM 
by enzymatic digestion using proteinase K, collagenase, or pepsin; MBV are isolated by successive 
centrifugation and ultracentrifugation [41].  Results from prior studies showed that the different 
enzymatic digestions affect the amount of extractable nucleic acids from ECM bioscaffolds, and 
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possibly alter the surface markers of MBV. Unlike the isolation of EVs from biological fluids, the 
separation of MBV from the ECM requires a disruption of the ECM fibrillar network by enzymatic 
digestion to release the MBV. This step alludes to the highly dynamic nature of the ECM, which 
is constantly undergoing remodeling processes. ECM degrading and remodeling enzymes are 
regulated in homeostasis and disease progression, which may be when MBV are being released 
for nearby cellular internalization and function. 
The present study compares the use of collagenase, elastase, and sodium chloride (NaCl) 
solution to solubilize the ECM for isolating MBV from urinary bladder matrix ECM (UBM-ECM). 
Herein, the effect of various enzymes or inorganic NaCl solution on the presence of lysyl oxidase 
(LOX) as a surface protein was investigated. LOX plays an integral role in ECM remodeling and 
ultimately determines the extent of intermolecular cross-linking between collagens and elastin. 
The presence or absence of LOX associated to the surface of MBV uncovers more information 
about how MBV are integrated within the matrix and how they function differently than EVs found 
in biological fluids. 
5.2 Methods 
5.2.1 Experimental Design Overview 
The objective of the present study was to investigate different solubilization methods of 
ECM for isolation of MBV. In addition, the presence of LOX associated to MBV was investigated. 
UBM-ECM was used to compare the different solubilization methods. The experimental design is 
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summarized in Figure 1. Table 1 lists the different experimental techniques used with UBM-ECM, 





Figure 1. Experimental design overview. Decellularized ECM is lyophilized and comminuted into a powder. The 
ECM is then solubilized by either enzymatic digestion by collagenase or elastase, or incubated in NaCl solution. 
Then, the solution goes through centrifugation steps to form a pellet of MBV. Analyses of MBV include TEM, 
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Table 1. Description of experimental goals and techniques used for each type of ECM 
ECM sources Goals Experiments 
UBM-ECM To investigate different 
solubilization methods of ECM to 
isolate MBV-associated LOX 
Enzymatic digestion by 
collagenase or elastase, or 
incubation in high NaCl solution; 




To determine if LOX is associated 
on the surface or in the lumen of 
MBV 
Enzymatic digestion by elastase; 
immunoprecipitation 
 
5.2.2 Preparation of Urinary Bladder Matrix ECM (UBM-ECM) and Small Intestinal 
Submucosa ECM (SIS-ECM) 
Urinary bladder matrix ECM (UBM-ECM) was prepared as previously described [91], 
which involved mechanically removing the tunica serosa, tunica muscularis externa, tunica 
submucosa, and tunica muscularis mucosa from porcine urinary bladders. The remaining tissue 
consisting of the basement membrane and subjacent lamina propria of the tunica mucosa were 
decellularized by washing in 0.1% peracetic acid with 4% ethanol for 2 hours at 300 rpm. The 
tissue was then extensively rinsed with PBS and sterile H2O. UBM was then lyophilized and milled 
into particulate using a Wiley Mill with a #60 mesh screen.  
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Small intestinal submucosa ECM (SIS-ECM) was used in comparison with UBM-ECM 
for immunoprecipitation studies. SIS-ECM was prepared as previously described [92, 93], which 
involved mechanically removing the superficial layers of the tunica mucosa, the tunica serosa, and 
tunica muscularis externa. The remaining tissue includes the stratum compactum layer of the 
tunica mucosa, the tunica muscularis mucosa, and the tunica submucosa [94].  SIS was 
decellularized and disinfected by washing in 0.1% peracetic acid with 4% ethanol for 2 hours at 
300 rpm. The tissue was then extensively rinsed with PBS and sterile H2O. SIS was then 
lyophilized and milled into particulate using a Wiley Mill with a #60 mesh screen.  
5.2.3 Solubilization of UBM-ECM  
Briefly, 400 mg of lyophilized powdered UBM-ECM was enzymatically digested with 
either 0.1 mg/ml collagenase from clostridium histolyticum (Sigma, C0130) in buffer (20 mM Tris 
pH 7.5, 150 mM NaCl, 5 mM CaCl2), or 4 μg/ml elastase (Elastin Products Company, SE563) in 
buffer (20 mM Tris pH 7.5, 150 mM NaCl), or incubated in 0.5 M NaCl for 20 hours at 37C on 
an orbital rocker (Table 2).  
 




Collagenase 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM CaCl2 0.1 mg/ml 
Elastase 20 mM Tris pH 7.5, 150 mM NaCl 4 μg/ml 
NaCl solution NaCl dissolved in Type I H2O 0.5 M 
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5.2.4 Isolation of MBV 
MBV were isolated from ECM by ultracentrifugation as previously described with minor 
modifications [41]. The solubilized UBM-ECM was then subjected to centrifugation at 10,000 xg 
for 30 minutes to remove insoluble ECM remnants, and the supernatant passed through a 0.22 m 
filter (Millipore). The clarified supernatant containing the liberated MBV was then centrifuged at 
100,000 xg (Beckman Coulter Optima L-90K Ultracentrifuge) at 4C for 70 minutes to pellet the 
MBV. The MBV pellet was then resuspended in 1X PBS and the total protein concentration 
determined using the bicinchoninic acid (BCA) assay quantification kit (Pierce Chemical). Particle 
size and concentration were determined using Nanoparticle Tracking Analyses (NTA) [54]. 
Samples were evaluated in triplicate. 
5.2.5 Transmission Electron Microscopy (TEM) 
MBV size and morphology was determined by transmission electron microscopy (TEM). 
Briefly, suspended MBV were placed on formvar-coated grids with 1% uranyl acetate for negative 
staining. Grids were imaged at 80 kV with a JEOL 1400 transmission electron microscope (JEOL 
Peabody, MA) with a side mount AMT 2k digital camera (Advanced Microscopy Techniques, 
Danvers, MA). Size of MBV was determined from representative images using JEOL TEM 
software.  
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5.2.6 Western Blot Analysis 
MBV were isolated by the different solubilization methods and ultracentrifugation as 
described in the previous sections. 1 x 109 particles/ml of MBV were resuspended in Laemmli 
buffer containing 5% -mercaptoethanol (Sigma-Aldrich). Samples were loaded in triplicate for 
each solubilization method. Samples were resolved by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) in 4-20% Mini-PROTEAN TGXTM Stain-Free polyacrylamide gels 
(Bio-Rad). Gels were run at 150 V in running buffer (25 mM Tris, 190 mM glycine, 0.1% SDS) 
and transferred on to a PVDF membrane for 3 hours at 150 mA in transfer buffer (25 mM Tris, 
190 mM glycine, 20% methanol). Membranes were analyzed by immunoblot (Western blot) using 
1:1000 dilution of LOX antibody (LS-Bio, LS‑C141072) in blocking buffer (5% non-fat milk in 
TBS) overnight at 4°C. Membranes were washed thoroughly in 0.1% Tween-20 in TBS and 
incubated with 1:2000 dilution of horseradish peroxidase secondary antibody (Dako) in blocking 
buffer for 1 hour at room temperature. Bio-Rad Western ECL solution (Bio-Rad, Hercules, MA) 
was applied to each membrane for 5 minutes before imaging. 
5.2.7 Immunolabeling 
MBV (2.5 x 109 particles/ml) were loaded on formvar-coated grids and decanted with filter 
paper after 60 seconds. Grids containing samples were fixed in 2% paraformaldehyde for 10 
minutes at room temperature, followed by successive washes in 1X PBS and BSA. All wash 
solutions were filtered through 0.45 µm filter. Samples were exposed to normal goat serum for 30 
minutes before addition of biotin conjugated primary antibody to LOX (20 µg/ml, LSBio, LS-
C141072) for 1 hour at room temperature. Grids were then washed in BSA before the addition of 
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Alexa Fluor 488 colloidal gold conjugate (ThermoFisher, A32361). Grids were thoroughly washed 
with BSA and 1X PBS before fixing in 2.5% glutaraldehyde. Samples were rinsed with deionized 
H2O before and between negative staining with 2% neutral uranyl acetate for 7 minutes, then 4% 
uranyl acetate for 2 minutes. Samples were dried with filter paper before imaging with TEM. For 
all samples, primary delete samples confirmed the absence of positive labeling of the secondary 
antibody. 
5.2.8 Immunoprecipitation 
MBV were isolated from UBM-ECM and SIS-ECM by the elastase digestion method and 
immunoprecipitation (IP) using magnetic Dynabeads coupled to Protein G (ThermoFisher 
Scientific). The magnetic beads were immunolabeled with anti-LOX (LifeSpan BioSciences, 
aa305-320) and immunoglobulin G (IgG) (ThermoFisher Scientific, A16110) as a negative 
control. Samples were imaged by TEM for presence of MBV and characterization of their 
morphology at 80,000X magnification.  
 
5.3 Results 
5.3.1 MBV can be Isolated from ECM by Various Solubilization Methods 
MBV were isolated from UBM-ECM by enzymatic digestion using collagenase or elastase, 
or incubation by a high salt solution. Prior studies have successfully isolated MBV by using 
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collagenase digestion of ECM before obtaining MBV by ultracentrifugation [41, 56]. The present 
study shows that MBV can be isolated after elastase as well as collagenase digestion of the ECM. 
Alternatively, high concentrations of NaCl can be used to solubilize the ECM and as an elution 
buffer to dissociate MBV from the fibrils. Herein, we show the size and morphology of MBV are 
consistent with previous reports [95] by TEM imaging (Figure 2A, C, E). NTA was performed on 
samples for particle concentration and distribution of particle size, which showed average vesicle 
size range of 120-190 nm in diameter (Figure 2B, D, F). BCA results showed higher protein 
concentrations for enzymatically digested samples compared to MBV isolated by NaCl solution 
(Figure 2G). 
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Figure 2. MBV can be isolated from UBM-ECM by enzymatic digestion using (A, B) collagenase or (C,D) elastase 
or using an elution buffer of  (E,F) 0.5 M NaCl. The morphology and size of the vesicles were confirmed by TEM 









MBV Particle per ug of 
Protein
Collagenase 982.11 9.50E+10 9.67E+7
Elastase 809.23 4.01E+11 4.96E+8
NaCl 63.54 1.31E+11 2.06E+9
G
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5.3.2 MBV-Associated LOX is Present in Pro-Peptide Form when Isolated with Elastase 
MBV-associated LOX was identified in the 52 kDa pro-peptide form when isolated with 
elastase digestion. Western blot analyses show a degraded 32 kDa form of LOX when MBV were 
isolated with collagenase digestion (Figure 3A). To determine the effect of ECM solubilization 
methods upon MBV-associated LOX, ECM was digested with elastase, collagenase, or NaCl. 
MBV-associated LOX was present in the samples digested with elastase Neither collagenase nor 
NaCl isolation methods yielded significant amounts of MBV-associated LOX as determined by 
Western blot analyses (Figure 3B). 
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Figure 3. LOX is associated with MBV isolated from elastase digestion. (A) LOX is present in its pro-peptide 
form (52kDa) while (B) it is degraded or eluted with collagenase digestion or NaCl, respectively.  
5.3.3 LOX is Associated on the Surface of MBV 
Results from immunolabeling and immunoprecipitation studies show that LOX is 
associated on the surface of MBV. TEM images from immunolabeling experiments showed 
positive labeling of gold particles, which are associated to LOX, in samples isolated with elastase 
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likely free LOX eluted off from MBV, not MBV-associated LOX. MBV isolated by collagenase 
digestion and treated with proteinase K had no signs of gold particles. MBV were not lysed and 
intact, which confirms that the binding streptavidin gold particles to biotin-conjugated LOX is on 
the surface MBV. 
Western blot analysis also confirm that MBV-associated LOX is on the surface. LOX was 
present in MBV isolated by the elastase digestion method and were absent in those treated with 
proteinase K (Figure 4B). Proteinase K acts as a broad spectrum protease and removes the surface 
proteins of MBV. 
In addition, TEM images from immunoprecipitation (IP) studies revealed presence of 
vesicles in UBM-ECM and SIS-ECM samples. Similar to the immunolabelling studies, MBV were 
not lysed and intact before precipitation of LOX. Results confirm that LOX precipitated with MBV 
isolated from UBM-ECM and SIS-ECM while immunoglobulin G (IgG) control samples had no 
presence of vesicles (Figure 4C). 
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Figure 4. (A) Immunolabelling was performed with biotin conjugated LOX and streptavidin gold particles (10 nm 
in diameter) to be imaged by TEM. Positive labeling of gold particles (red arrows) were shown in MBV isolated 
from elastase and were completely absent in collagenase samples. Gold particles appeared in NaCl samples but are 
likely free LOX eluted off from MBV. Gold particles were also absent in samples isolated by elastase digestion and 
treated with proteinase K. (B) Western blot analyses showed that LOX was associated with MBV digested by 
elastase and was absent on proteinase K treated samples. (C) MBV-associated LOX was immunoprecipitated from 
MBV isolated from urinary bladder matrix (UBM) and small intestinal submucosa (SIS)  by enzymatic digestion 
with elastase. All scale bars are 100 nm. 
5.4 Discussion 
The present study shows that MBV can be isolated from ECM by different solubilization 
methods. MBV have been reported to survive the various decellularization processes of ECM and 
were previously identified in several types of ECM bioscaffolds including urinary bladder matrix 
ECM (UBM-ECM), small intestinal submucosa ECM (SIS-ECM), and dermis ECM, along with 
their commercially available equivalent scaffolds [41]. Past studies involved the use of collagenase 
from clostridium histolyticum as an enzyme to disrupt the ECM prior to successive steps of 
centrifugation for isolation of MBV. In addition, enzymes such as pepsin and proteinase K were 
used to compare their effects on ECM bioscaffolds [41]. MBV were identified with unique 
signatures and miRNA cargo among the various ECM bioscaffolds, which may be, in part, due to 
the specific decellularization protocols and anatomic location of the source tissue. The present 
study investigates the effect of different solubilization methods on UBM-ECM for isolating MBV. 
Herein, MBV can be isolated by not only by enzymatic digestion of the ECM, but also by 
solubilization of ECM by solubilization in a high concentrated salt (NaCl) solution.  
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Herein, the presence of lysyl oxidase (LOX) as a surface protein was observed in MBV 
isolated with elastase digestion. We found the enzymatic activity and components of the 
collagenase enzyme had undesirable tryptic activity when digesting the ECM. The collagenase 
product is a mixture of enzymes secreted by clostridium histolyticum and contains trypsin-like 
proteases including clostripain, leucine aminopeptidase, and neutral proteases [96, 97].  It is 
plausible that the collagenase digestion method cleaves and removes the surface-bound proteins 
on MBV, which is undesirable for studying MBV-associated LOX. Using elastase from human 
sputum, which has been shown to function as a type of “collagenase” and cleave triple helical 
collagen [98], LOX was identified to be associated to the surface of MBV. However, the method 
of solubilization of ECM does influence the molecular weight of MBV-associated LOX. When 
elastase from human leucocytes is used to digest the ECM before MBV isolation, LOX is 
associated to the lipid membrane of MBV in its 52 kDa form. When collagenase is used to digest 
the ECM, LOX appears to be degraded and/or cleaved by various enzymatic products with tryptic 
activity. LOX is also eluted off MBV when solubilized in high concentration of NaCl solution. 
The expression of LOX is driven by hypoxia-inducible factors (HIFs) and gets glycosylated in the 
Golgi apparatus into its pro-peptide form [99, 100].   The identification of the pro-peptide LOX 
associated with MBV suggest that LOX may become associated to the surface of MBV during 
vesicle secretion into the extracellular space. LOX on the surface of MBV must be bound and 
interacting with another protein(s), which we have yet to identify. Further studies will be 
performed to identify MBV-associated LOX binding partners.    
Although the history of the LOX genome can be traced back to the pre-metazoan times 
[101], there is a limited amount of information about the enzymatic mechanism of LOX and the 
variability of the protein across tissues and different species [102, 103].  In addition, there are 
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significant challenges associated with the isolation and purification of LOX. LOX is highly 
insoluble in aqueous buffers and it has been difficult to obtain large quantities of the enzymatically 
active recombinant protein [58]. Prior studies have used lengthy dialysis procedures that require 
multiple buffers and refolding of the protein and extraction using high concentration of urea [104-
106]. More recently, solubility tags have been incorporated in buffers to purify enzymatically 
active LOX, but have resulted in a decreased yield of protein [58]. Results reported herein 
represent the first identification of MBV-associated LOX and offer insights into the mechanisms 
by which LOX is incorporated into the extracellular space.  
5.5 Conclusions 
Results from the present study show that MBV can be isolated by various digestion and 
solubilization methods of ECM. Specifically, ECM can be enzymatically digested by collagenase 
and elastase, along with solubilization by high concentration of salt solution. Results identified 
that LOX is associated to the surface of MBV by elastase digestion, whereas it is degraded or 
eluted off the surface of MBV by the other methods. Such implications provide insights into how 
LOX is associated to extracellular vesicles such as MBV and incorporated in the extracellular 
milieu, which is not fully understood and requires further investigation.  
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6.0 Matrix-Bound Nanovesicles in Native Porcine Tissues 
6.1 Introduction 
Matrix-bound nanovesicles (MBV) are relatively a new discovery in the field of 
extracellular vesicles. MBV have been described as bioactive components of the matrix, where 
they can recapitulate the biologic effects of the parent ECM, including differentiation of neural 
stem cells and modulation of macrophage phenotype [41, 56].    
Studies have successfully isolated MBV from decellularized ECM from various tissue 
sources. Although MBV were discovered to be retained embedded in the matrix after the 
decellularization process, it is possible that the quality of the vesicles and their surface proteins 
may be affected or subjected to degradation. Herein, it is hypothesized that the specific 
decellularization process on tissues may affect the presence of LOX associated to the surface of 
MBV.  The present study shows that MBV can be isolated from native porcine tissues without 
processing by decellularization. Results show that MBV are present in a variety of tested source 
tissue. The concentration of MBV and total protein content varied from tissue to tissue. Because 
MBV were isolated from native tissues, these results cannot be attributed to tissue-specific 
decellularization processes, but rather, tissue-specific biological composition and function. 
Isolating MBV directly from native tissues provide insights for future studies investigating MBV-
associated surface proteins that may be subjected to degradation by the decellularization process.  
  32 
6.2 Materials and Methods 
6.2.1 Isolation of MBV from Native Porcine Tissues 
To determine if the decellularization process affects the quality and enzymatic activity of 
MBV-associated LOX, MBV were isolated from a variety of native porcine tissues. MBV were 
isolated from non-decellularized porcine tissues, including brain, bladder, heart, skeletal muscle, 
ovary, pancreas, small intestine, and Achilles tendon. For all tissue types, 2 g of wet weight 
samples were finely minced and rinsed with PBS before enzymatically digested by 4 μg/ml elastase 
in buffer [20 mM Tris (pH = 7.5), 150 mM NaCl] for 20 hours at 37°C on an orbital rocker. 
Samples were sequentially centrifuged at 500 xg for 5 minutes, 2,500 xg for 20 minutes, and 
10,000 xg for 30 minutes (3 times) at 4°C to remove cells and large debris. Samples were then 
passed through a 0.2 µm filter and ultracentrifuged at 100,000 xg for 70 minutes at 4°C. MBV 
pellets were resuspended in PBS. Particle size and concentration were determined using 
Nanoparticle Tracking Analyses (NTA) [54] and bicinchoninic acid (BCA) assays. Samples were 
evaluated in biological triplicates. 
6.2.2 Transmission Electron Microscopy (TEM) 
MBV samples were imaged by TEM as previously described. Briefly, re-suspended MBV 
were placed on formvar-coated grids with 1% uranyl acetate for negative staining. Grids were 
imaged at 80 kV with a JEOL 1400 transmission electron microscope (JEOL Peabody, MA) with 
a side mount AMT 2k digital camera (Advanced Microscopy Techniques, Danvers, MA). Size of 
MBV was determined from representative images using JEOL TEM software.  
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6.2.3 Western Blot Analysis 
1 x 109 particles/ml of MBV isolated from each tissue were resuspended in Laemmli buffer 
containing 5% β-mercaptoethanol (Sigma-Aldrich). Samples were resolved by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in a 4-20% Mini-PROTEAN TGXTM 
Stain-Free polyacrylamide gel (Bio-Rad) at 150 V in running buffer (25 mM Tris, 190 mM glycine, 
0.1% SDS) and transferred on to a PVDF membrane for 3 hours at 150 mA in transfer buffer (25 
mM Tris, 190 mM glycine, 20% methanol). Membranes were analyzed by Western blot using 
1:1000 dilution of LOX antibody (LS-Bio, LS‑C141072) in blocking buffer (5% non-fat milk in 
TBS) overnight at 4°C. Membranes were washed thoroughly in 0.1% Tween-20 in TBS and 
incubated with 1:2000 dilution of horseradish peroxidase secondary antibody (Dako) in blocking 
buffer for 1 hour at room temperature. Bio-Rad Western ECL solution (Bio-Rad, Hercules, MA) 
was applied to each membrane for 5 minutes before imaging. 
6.3 Results 
6.3.1 MBV Isolated from Native Porcine Tissues Contain MBV-associated LOX 
In order to compare MBV isolated from different porcine tissues without any effects from 
the decellularization process, MBV were isolated from whole porcine tissues that did not undergo 
processing by decellularization protocols. Porcine tissues varying in anatomical location (i.e., 
bladder, brain, heart, muscle, ovary, pancreas, small intestine, and tendon) were enzymatically 
digested by elastase before isolation of MBV. TEM imaging confirmed the presence of rounded 
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structures that are similar in size and shape of previously reported MBV [41] (Figure 5). Results 
from NTA showed similar particle concentrations across all tissue samples except brain tissue. 
Brain tissue is likely to have more remnant lipids and other proteins in the sample. BCA analyses 
showed total protein concentrations vary between the tissue samples. These results are shown in 
Table 2 and displayed in Figure 6 below. Our results show not only the heterogeneity of MBV that 






Figure 5. MBV isolated from various native porcine tissues. Transmission electron microscopy (TEM) images 
confirm the presence of MBV in all porcine tissue samples (scale bars = 100 nm). 
 
Bladder Brain Heart Muscle
Ovaries Pancreas Small intestine Tendon
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Table 3. Quantification of protein and particle concentrations of MBV isolated from native porcine tissues 




MBV Particle per µg of 
Protein 
Bladder 3671.57 5.09E+12 1.39E+09 
Brain 756.35 5.57E+11 7.37E+08 
Heart 903.00 3.41E+11 3.78E+08 
Skeletal muscle 1142.50 3.60E+11 3.15E+08 
Ovary 484.81 2.76E+11 5.70E+08 
Pancreas 500.15 6.45E+11 1.29E+09 
Small intestine 1621.78 8.14E+11 5.02E+08 
Tendon 279.00 7.95E+10 2.85E+08 
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Figure 6. Quantification of particle and total protein quantification of MBV isolated from native porcine 
tissues. 
6.3.2 MBV-Associated LOX is Present in a Variety of Tested Source Tissue  
The presence of MBV-associated LOX in native porcine tissues was investigated. Results 
from Western blots showed differential products of LOX in varying molecular weights and 
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of LOX [107], or non-specific binding of the antibody. Further experiments are required to validate 
the results and optimize the experiment using different LOX antibodies. 
 
Figure 7. Presence of MBV-associated LOX in native porcine tissues. 
 
The present study investigates MBV isolated from native porcine tissues, of which they 
were not decellularized previously. The preparation of ECM bioscaffolds requires intensive 
processing steps, where the decellularization process includes physical, chemical, mechanical 
methods of processing and manufacturing. A list of various decellularization processes are 
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excess tissue and various chemicals and detergents. Then, the samples are frozen and lyophilized 
into a dry state to allow mechanical comminution into a powder.  
 
Table 4. Decellularization processes for various tissues 
Tissue Source Decellularization Process Reference 
Urinary bladder Mechanical removal of muscular layers; 0.1% 
peracetic acid and water washes 
[108] 
Small intestine Mechanical removal of muscular layers; 0.1% 
peracetic acid and water washes 
[94] 
Dermis Mechanical removal of fat, connective tissue, and 
epidermis; washes with 0.25% trypsin, 70% ethanol, 
3% H2O2, 1% Triton X-100, 0.26% EDTA/0.69% Tris, 
0.1% peracetic acid/0.4% ethanol, water, and PBS 
 
[109] 
Skeletal muscle Mechanical removal of fat and connective tissue; 
washes with 2:1 v/v chloroform/methanol, graded 
series of ethanol, 0.2% trypsin/0.2% EDTA, 2% 
sodium deoxycholate, 1% Triton X-100, 0.1% 
peracetic acid/4% ethanol, water and PBS 
 
[110] 
Brain Mechanical removal of dura matter; washes with 
0.02% trypsin/0.05% EDTA, 3% Triton X-100, 1 M 




Esophagus Mechanical removal of muscularis layer; washes 
with 1% trypsin/0.05% EDTA, 1 M sucrose, 3% 
Triton X-100, 10% deoxycholate, 0.1% peracetic 
acid, 4% ethanol, 100 U/ml DNAse, water, and PBS 
[111] 
 
The effects of decellularization on the resulting biologic scaffold and the associated host 
remodeling response have been reported [112, 113]. Decellularization of ECM bioscaffolds is in 
fact critical for avoiding inflammatory responses that can mitigate or completely inhibit 
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constructive remodeling events. For example, macrophages are key players in the host response 
and are activated in the presence of tissue damage, inflammation, and infection. Macrophages 
subsequently release a variety of cytokines and chemokines [114] that also influence the tissue 
repair and remodeling process, particularly in the presence of biologic scaffolds [40, 115]. The 
presence of allogeneic or xenogeneic cells within a biologic scaffold has been associated to pro-
inflammatory cytokines, increased M1-like macrophage polarization, and poor remodeling 
outcomes [116]. Although the importance of decellularization in ECM biologic scaffolds is clear, 
it is not known if decellularization of tissues is required for isolation of MBV for therapeutic 
applications. MBV are secreted by tissue-resident cells and integrated into the fibrillar matrix, 
from which they can be isolated by enzymatic digestion. It is plausible that decellularization of 
tissues is not required prior to isolation of MBV.  
The present study presents MBV isolated from native porcine tissues including bladder, 
brain, heart, skeletal muscle, ovary, pancreas, small intestine, and Achilles tendon. Although the 
number of MBV particles were similar across tissue sources, total protein concentrations varied. 
When MBV-associated LOX was investigated by Western blot analyses, LOX was found to be 
present in varying amounts and differential forms or degraded products. Because the MBV 
samples were isolated directly from native tissue, the variable of the effects induced by the 
decellularization process can be omitted. The presence of MBV-associated LOX is likely due to 
the source tissue’s biological composition and function. For example, brain tissue, which is made 
of primarily fat with very little matrix, has hardly any LOX, whereas the heart, which is a tissue 
that has an extensive ECM and experiences constant mechanical force, has higher amounts and 
differential products of LOX. This indicates that MBV contain different cargo along with its 
membrane-bound surface proteins for tissue-specific functions. 
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6.4 Conclusions 
Results of the present study show, for the first time, MBV isolated from native porcine 
tissues that were not decellularized. Removing the decellularization step prior to isolating MBV 
allows investigation of MBV that were not subjected to tissue-specific decellularization protocols. 
MBV were found to vary in total protein concentrations anatomically different source tissues, 
including bladder, brain, heart, skeletal muscle, ovary, pancreas, small intestine, and Achilles 
tendon.  Further, MBV-associated LOX appeared in different amounts and molecular weights 
between the tissue samples. The findings reported show the heterologous nature of MBV in and 
associated LOX among the diverse tissue sources. 
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7.0 Isolation f MBV-Associated LOS from ECM Bioscaffolds 
7.1 Introduction 
Lysyl oxidase (LOX) is a copper dependent enzyme that catalyzes the cross-linking of the 
molecular units of collagen and elastin, which is an essential post-translational modification that 
occurs in the biogenesis of collagenous connective tissues [18]. LOX causes the oxidative 
deamination of peptidyl-lysine and hydroxylysine to peptidyl--aminoadipic--semialdehyde, 
which is the precursor to various cross-links in collagen and elastin [117]. The LOX family of 
proteins exist in 5 different isoforms in mammalians, LOX and LOX-like isoforms 1-4 (LOXL1-
4) [118]. Full characterization and understanding of the enzyme’s catalytic activity remain 
unknown due to its highly insoluble properties and difficulties in obtaining large quantities of LOX 
[58]. Isolation of LOX procedures from tissue involve high concentrations of urea and extensive 
buffer exchanges [59, 60]. Nevertheless, it is widely reported that LOX is essential for proper ECM 
development and stabilization of tissues [8, 61, 62]. 
LOX has been identified in several proteomic analyses studies of ECM including Matrigel 
[70], ECM-produced by synovium-derived stem cells [71], and ovine forestomach matrix [72]. 
Biologic scaffolds composed of ECM have been used as surgical meshes and inductive templates 
for tissue remodeling in multiple anatomic sites, including rotator cuff, Achilles tendon, tibialis 
posterior, patellar tendons, and hernia, among others [119-122]. ECM scaffolds promote 
constructive tissue remodeling and at least partial restoration of function. The present study reports, 
for the first time to the best of our knowledge, an extracellular source of LOX associated to the 
ECM, specifically matrix-bound nanovesicles (MBV), which are lipid-bound extracellular vesicles 
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described as an integral component of the ECM. Recent studies attribute certain aspects of the 
constructive remodeling events to MBV have been shown to modulate cell behavior as a function 
of their internal cargo of biologically active signaling molecules (e.g. microRNAs) [41]. MBV 
influence neuron differentiation and promote a pro-remodeling macrophage phenotype [41, 55-
57]. MBV are secreted by tissue-resident cells and integrated in the ECM, which make them 
distinctly different from extracellular vesicles existing in fluid (i.e., exosomes) [53]. The 
integration of MBV in the fibrillar matrix may be due to the surface proteins and constituent 
phospholipids, which may differ as a function of anatomic location from which the MBV are 
harvested. Such differences are important factors when considering potential therapeutic 
applications of MBV to deliver internal cargo or surface proteins to promote ECM remodeling and 
functional restoration. The goal of the present study was to identify MBV-associated LOX in 
various biologic scaffolds and compare the abundance of associated LOX proteins. 
7.2 Methods 
7.2.1 Preparation of ECM Bioscaffolds 
Urinary bladder matrix ECM (UBM-ECM) – UBM-ECM was prepared as previously 
described [91]. The specific procedure of preparing UBM-ECM is detailed previously in section 
5.2.2. 
Small intestinal submucosa ECM (SIS-ECM) – SIS-ECM was prepared as previously 
described [92, 93]. Briefly, the superficial layers of the tunica mucosa, the tunica serosa, and tunica 
muscularis externa were mechanically removed. The remaining tissue was decellularized and 
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disinfected by washing in 0.1% peracetic acid with 4% ethanol for 2 hours at 300 rpm. The tissue 
was then extensively rinsed with PBS and sterile H2O. SIS-ECM was then lyophilized and milled 
into particulate using a Wiley Mill with a #60 mesh screen.  
Dermis ECM (dECM) – dECM was prepared as previously described [109]. Briefly, the 
epidermis, connective tissue, and subcutaneous fat were removed by mechanical delamination. 
The remaining tissue was decellularized by washing in 0.25% trypsin for 6 hours, 70% ethanol for 
10 hours, 3% H2O2 for 15 minutes, 1% Triton X-100 in 0.26% EDTA/0.69% tris for 6 hours with 
a solution change for an additional 16 hours, and 0.1% peracetic acid/4% ethanol for 2 hours. All 
chemical exposures were conducted at 300 rpm in an orbital shaker. dECM was extensively 
washed with sterile H2O and PBS between chemical exposures. dECM was then lyophilized and 
milled into particulate using a Wiley Mill with a #60 mesh screen. 
Tendon ECM (tECM) – tEM was prepared by a vacuum-assisted method [123]. Briefly, 
muscle, fat, synovial sheath, and para-tenon were aseptically dissected from Achilles tendons. 
Decellularization was performed in a container capable of withstanding negative pressure/vacuum 
(e.g. desiccator) attached to a Welch 8925 DirecTorr Vacuum Pump (Gardner Denver Thomas, 
Inc. a division of Ingersoll Rand, Mt. Prospect, IL) fitted with a pressure gauge (Nagano Keiki Co. 
Ltd., Japan), controlled by a custom LabView (National Instruments, Austin, TX) program. A 
vacuum was created to approximately 100 kPa (~30" Hg). The prepared tendons were placed in a 
beaker with 300 mL of 12.5% NaCl. The vacuum parameters were 480 cycles, 120 seconds per 
cycle with 75% duty load. Tissues were then washed in H2O on an orbital shaker for 1 hour at 
room temperature. Tissues were placed in 12.5% NaCl in the vacuum for 180 cycles 3 more times 
with H2O washes in between. 
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All prepared scaffolds met stringent requirements for sufficient decellularization; 
specifically, no visible intact nuclei by DAPI and hematoxylin and eosin (H&E) staining, remnant 
DNA concentration <50 ng/mg total scaffold dry weight, and DNA fragment length <200 base 
pairs [124]. 
7.2.2 Isolation of MBV 
MBV were isolated from decellularized porcine ECM bioscaffolds and some of their 
commercially available equivalents by enzymatic digestion as previously described with minor 
modifications [41]. Briefly, 400 mg of lyophilized powdered ECM was enzymatically digested 
with 4 μg/ml elastase (Elastin Products Company, SE563) in buffer (20 mM Tris pH 7.5, 150 mM 
NaCl) for 20 hours at 37°C on an orbital rocker. Samples were sequentially centrifuged at 500 xg 
for 5 minutes, 2,500 xg for 20 minutes, and 10,000 xg for 30 minutes (3 times) at 4°C. Samples 
were then passed through a 0.2 µm filter and ultracentrifuged at 100,000 xg for 70 minutes at 4°C. 
MBV pellets were resuspended in PBS. Particle size and concentration were determined using 
Nanoparticle Tracking Analyses (NTA) [54] and bicinchoninic acid (BCA) assays. Samples were 
evaluated in triplicate. 
7.2.3 Transmission Electron Microscopy (TEM) 
MBV samples were imaged by TEM as previously described. Briefly, re-suspended MBV 
were placed on formvar-coated grids with 1% uranyl acetate for negative staining. Grids were 
imaged at 80 kV with a JEOL 1400 transmission electron microscope (JEOL Peabody, MA) with 
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a side mount AMT 2k digital camera (Advanced Microscopy Techniques, Danvers, MA). Size of 
MBV was determined from representative images using JEOL TEM software.  
7.2.4 SDS-PAGE and Silver Stain  
1 x 109 particles/ml of MBV isolated from each tissue were resuspended in Laemmli buffer 
containing 5% β-mercaptoethanol (Sigma-Aldrich). Samples were resolved by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in a 4-20% Mini-PROTEAN TGXTM 
Stain-Free polyacrylamide gel (Bio-Rad) at 150 V in running buffer (25 mM Tris, 190 mM glycine, 
0.1% SDS). For silver stain, gels were stored in fixing buffer overnight and then stained with a 
Pierce Silver Stain for Mass Spectrometry Kit (Life Technologies) following the manufacturer’s 
instructions. For Western blot analyses, gels were transferred on to a PVDF membrane for 3 hours 
at 150 mA in transfer buffer (25 mM Tris, 190 mM glycine, 20% methanol). Membranes were 
analyzed by Western blot using 1:1000 dilution of LOX antibody (LS-Bio, LS‑C141072), 1 μg/ml 
LOXL1 antibody (LS-Bio, LS-C110889), 1:1000 dilution of LOXL2 antibody (LS-Bio, LS-
C369938), 1 μg/ml LOXL3 antibody (LS-Bio, LS-C135755), or 1:400 dilution of LOXL4 
antibody (LS-Bio, LS-C295249) in blocking buffer (5% non-fat milk in TBS) overnight at 4°C. 
Membranes were washed thoroughly in 0.1% Tween-20 in TBS and incubated with 1:2000 
dilution of horseradish peroxidase secondary antibody (Dako) in blocking buffer for 1 hour at room 
temperature. Bio-Rad Western ECL solution (Bio-Rad, Hercules, MA) was applied to each 
membrane for 5 minutes before imaging.  
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7.2.5 Enzyme-Linked Immunosorbent Assay (ELISA)  
Enzyme-linked immunosorbent assay (ELISA) was used to determine the concentrations 
of MBV-associated LOX in UBM, SIS, dECM, and tECM. After isolation, resuspended MBV 
were used to perform ELISAs following specific manufacturing instructions (LS-Bio, LS-F53541). 
Samples were evaluated in quadruplicate.  
7.3 Results 
7.3.1 MBV Isolated from Various ECM Bioscaffolds 
MBV were isolated and the presence of vesicles were confirmed by TEM (Figure 8A). 
Images showed that proteinase K does not disrupt the integrity or morphology of vesicles. Particle 
concentration of each samples were quantified by NTA and vesicles were an average size 90 – 200 
nm in diameter (Figure 8B). Samples were evaluated in biologic triplicates. 
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Figure 8. MBV isolated from ECM bioscaffolds. (A) TEM images of MBV confirmed presence of vesicles in all 
samples, including those treated with proteinase K (scale bars = 100 nm) (B) NTA of MBV isolated from various 
ECM and their commercially available equivalents. 
7.3.2 Presence of LOX Isoforms in ECM Bioscaffolds 
Results from Western blot analyses showed the presence or absence of LOX isoforms. 
Specifically, LOX was found associated to MBV isolated from UBM and its commercially 
available equivalent Micromatrix®, SIS, and tECM at the 52 kDa pro-peptide form (Figure 9). The 
other LOX isoforms were not present as determined by Western blots. Results from ELISA showed 
that MBV-associated LOX was the most abundant in UBM compared to the other ECM samples 
(Figure 10). Data is shown with mean ± SD. 
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Figure 10. Quantification of MBV-associated LOX by ELISA. 
7.3.3 Identification of Binding Partners of MBV-Associated LOX 
A preliminary experiment was performed to identify the binding partners of MBV-
associated LOX by SDS-PAGE and silver stain (Figure 11). MBV samples have clear bands in 
above 49kDa, which do not appear in samples treated with proteinase k. Degradation products of 
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Figure 11. SDS-PAGE and silver stain of MBV-associated LOX. MBV samples have clear bands in above 
49kDa, which do not appear in samples treated with proteinase k (ProtK). Degradation products of proteinase K are 
shown below 20 kDa. 
7.4 Discussion 
The role of LOX in the cross-linking of collagen and elastin has been studied in multiple 
tissues including skin, lung, and cardiovascular tissues [125-127]; and is essential for stabilization 
of the ECM [78, 128-130]. Studies have been limited in fully characterizing LOX and its 
mechanism due to its highly insoluble properties [58]. In fact, the 3-dimensional model of LOX 
was only recently described, and has facilitated further studies of LOX, its protein interactions, 
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as porcine aorta [59], or expressed through in vitro systems to investigate biological functions and 
mechanism of LOX [58, 131].  
The challenges associated with the isolation and purification of LOX is widely known. 
LOX is highly insoluble in aqueous buffers and it has been difficult to obtain large quantities of 
the enzymatically active recombinant protein [58]. Prior studies have used lengthy dialysis 
procedures that require multiple buffers and refolding of the protein and extraction using high 
concentration of urea [104-106]. To the best of our knowledge, this is the first report describing a 
stable extracellular matrix-associated surface protein. The present study identifies the presence and 
abundance of LOX associated to MBV isolated from various ECM bioscaffolds. Herein, MBV-
associated LOX is present in varying amounts in different ECM, which may be due to tissue 
specificity/function or the effects of the decellularization process to produce ECM. 
MBVs are similar to exosomes in their nanometer size and containment of miRNA cargo 
but are different in which they lack common exosomal surface markers including CD63, CD81, 
CD9, and HSP70 [41]. The discovery MBV-associated LOX provides insights to the insoluble 
nature of LOX. It is plausible that, by association to the surface of MBV, the biological and 
functional role of LOX in cross-linking collagen is more controlled and tightly regulated to be 
shuttled directly to its specific matrix substrates. 
There are many limitations to the present study. Full comparison to commercially available 
ECM, such as for SIS and tECM, would have furthered characterization of MBV-associated LOX. 
The experiments performed were biological replicates but future work including technical 
replicates is required to validate the data. In addition, the antibodies for the different LOX isoforms 
should be optimized for further Western blot analyses. Future work will identify and confirm the 
presence or absence of the other LOX isoforms associated to MBV. Last but not least, further 
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analyses of the silver stain data are required. Future will identify immunoprecipitated binding 
partners my downstream mass spectrometry analyses. 
7.5 Conclusions 
Results of the present study show that MBV-associated LOX is present in UBM, SIS, 
dECM, and tECM. Specifically, MBV isolated from UBM showed the most abundant amount of 
LOX in the 52 kDa pro-peptide form. MBV-associated LOX also shows distinctly different protein 
signatures compared to those treated with proteinase K. The findings of this study reports, for the 
first time, an extracellular source of LOX associated to the ECM. MBV provide a unique and 
attractive way to isolate LOX for possible therapeutic applications. 
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8.0 Enzymatically Active LOX Associated to Matrix-Bound Nanovesicles 
8.1 Introduction 
As iterated in previous chapters, lysyl oxidase (LOX) is an extracellular enzyme 
responsible for catalyzing the covalent cross-linking of collagen, which is an essential post-
translational modification to the stabilization of tissues. The enzymatic role LOX plays in the 
extracellular space has long been studied but complete understanding of its biosynthesis, 
mechanism of action, co-factors, and substrate specificity is still necessary. 
The synthesis and processing of LOX involves multiple processes that are commonly 
known with protein syntheses. LOX is synthesized in the cell cytoplasm and glycosylated before 
entering the Golgi apparatus, where it is processed to its inactive 52 kDa pro-peptide from [100]. 
This pro-peptide is secreted into the extracellular space, where it is cleaved and activated by pro-
collagen C proteinases (e.g. BMP-1, TLL1, TLL2 [132]) to the 32 kDa enzymatically active form 
of LOX. BMP-1 has been most commonly reported to be involved in the proteolytic processing of 
the LOX precursor to [77, 79, 100]. However, recent studies have reported proteolysis of LOX 
occurs by alternative cleavage sites, specifically, downstream of the BMP-1 cleavage site [133]. 
This processing of LOX did not significantly affect the enzymatic activity, but rather modified the 
affinity towards collagen. In addition, and most interestingly, the LOX precursor was shown to be 
enzymatically active without the necessity of proteolysis. 
The present study succeeds the findings of previous chapters reporting LOX associated to 
the surface of matrix-bound nanovesicles. Specifically, the enzymatic and functional activity of 
MBV-associated LOX, which was identified as the 52 kDa pro-peptide form, was investigated. 
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MBV-associated LOX was also determined for its effect upon collagen strength in an in vitro 
collagen construct model. The synthesis of collagen secretion from cells, and the subsequent 
assembly and cross-linking of fibers have been exhaustively studied. However, the mechanism by 
which extracellular fibrils self-assemble and form covalent cross-links in vivo is largely unknown.  
Herein, we identify the pro-peptide form of MBV-associated LOX is enzymatically active and has 
biologic effects on collagen construct development in vitro. 
8.2 Methods 
8.2.1 Preparation of Urinary Bladder Matrix (UBM) 
Urinary bladder matrix (UBM) was prepared as previously described [91]. The specific 
procedure of preparing UBM-ECM is detailed previously in section 5.2.2. 
8.2.2 Isolation of MBV-Associated LOX 
MBV were isolated by enzymatic digestion using 4 μg/ml elastase (Elastin Products 
Company, SE563) in buffer (20 mM Tris pH 7.5, 150 mM NaCl) for 20 hours at 37C on an orbital 
rocker. The digested ECM was then subjected to centrifugation at 10,000 xg for 30 minutes to 
remove insoluble ECM remnants, and the supernatant passed through a 0.22 m filter (Millipore). 
For preparing negative control samples, MBV were treated with 0.1 mg/ml proteinase K in buffer 
(20 mM Tris pH 7.5, 150 mM NaCl) for 1 hour at 37C on an orbital rocker, which removed MBV 
surface proteins. The clarified supernatant containing the liberated MBV was then centrifuged at 
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100,000 xg (Beckman Coulter Optima L-90K Ultracentrifuge) at 4C for 70 minutes. The MBV 
pellet was then resuspended in 1X PBS and the total protein concentration determined using the 
bicinchoninic acid (BCA) assay quantification kit (Pierce Chemical). Particle size and 
concentration were determined using Nanoparticle Tracking Analyses (NTA) [54]. Samples were 
evaluated in triplicate. 
8.2.3 Inhibition of LOX Activity 
After resuspending in PBS, MBV-associated LOX samples were lysed in buffer containing 
150 mM NaCl, 1% Triton, and 50 mM Tris (pH = 8) using a sonic dismembrator (Fisherbrand™). 
Samples were centrifuged at 13,000 xg at 4C for 5 minutes. The supernatant was collected and 
kept on ice. Samples were treated with 0, 5, 10, 20, 50, 100, 250, or 500 μM of irreversible LOX 
inhibitor β-aminopropionitrile (BAPN) at 37C overnight. Samples were assessed for enzymatic 
activity of LOX using the Lysyl Oxidase Activity Assay Kit (Abcam, ab112139) per 
manufacturer’s instructions. All samples were evaluated in triplicate. 
8.2.4 Isolation of Primary Tenocytes 
Primary tenocytes were isolated from rat tendons as previously described with slight 
modifications [134]. Rat tails were obtained from Sprague-Dawley rats that were euthanized for 
reasons unrelated to the present study, and the tendons were separated from their outer sheaths into 
a dish containing 1X PBS + 1% antibiotic-antimycotic (ThermoFisher Scientific) to remove 
unwanted debris and contaminants (Figure 12A).  After rinsing in PBS, tendons were digested in 
3 mg/mL collagenase from clostridium histolyticum (Sigma-Aldrich, C0130) in buffer containing 
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20 mM Tris (pH = 7.5), 150 mM NaCl, and 5 mM CaCl2 in high glucose DMEM (ThermoFisher 
Scientific) on an orbital rotator at 37°C for 4 hours. The digested tendons were passed through a 
70 μm cell strainer (ThermoFisher Scientific) and centrifuged at 1.4 xg for 5 minutes. The cell 
pellet was resuspended in media consisting of DMEM, 20% fetal bovine serum (FBS) (Invitrogen), 
and 1% antibiotic-antimycotic, and counted using a hemocytometer. Cells were plated at 1 x 106 
cells in T25 culture flasks and maintained at 37°C and 5% CO2 with complete medium change 
every 2 days for 4 days. 
 
Figure 12. Isolation of tenocytes. (A) Primary tenocytes were isolated from rat tail tendons digested in collagenase. 
(B) Cells were used for producing in vitro tendon constructs in 6-well plates coated with Sylgard, with 2 silk sutures 
pinned 1 cm apart. 
 
8.2.5 In Vitro Collagen Fibril Formation 
When primary tenocytes were confluent, tenocytes were disassociated by trypsin and used 
for the self-organizing collagen construct system [7, 135]. A 6-well culture plate was coated with 
1.5 mL of SYLGARD®184 (Sigma-Aldrich, 761036) and allowed to set at 37°C for 48 hours. Two 
silk sutures, separated by 1.0 cm, were pinned to the coated plates (Figure 12B). The plates were 
washed in 70% ethanol for 45 minutes, exposed to UV for 1 hour, and washed with sterile PBS. 
A B
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Primary tenocytes were suspended in culture medium containing 50 mg of human fibrinogen, 10 
μg/ml aprotinin, and 1 unit of human thrombin (all from Sigma Aldrich) and allowed to set in 
culture for 30 minutes at 37°C. Media was added to the surface of cell-fibrinogen culture as needed 
to prevent drying. Media was changed every other day, with the addition of 0.33 mM L-ascorbic 
acid 2-phosphate 33.3 μM L-proline (both from Sigma Aldrich). 1 x 109 particles/ml UBM-ECM 
MBV isolated from UBM-ECM were added during media changes after the cell-fibrinogen 
cultures were plated. 
8.2.6 Histology 
Collagen constructs were harvested and fixed in 10% neutral buffered formalin (NBF) for 
at least 7 days. Samples were then embedded in paraffin, cut into 5 μm longitudinal sections, and 
mounted onto glass slides for Masson’s trichrome staining. 
8.2.7 Quantification of Soluble Collagen 
Soluble collagen content was determined in 7 day collagen constructs using Sircol™ 
Soluble Collagen Assay kit (Biocolor). Samples were treated with 1 x 109 particles/ml MBV, MBV 
treated with 500 μM BAPN, MBV treated with 0.1 mg/ml proteinase K, or media as controls. 
Constructs were harvested from the plates and rinsed in 1X PBS and stored at -20°C prior to 
experiments.   
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8.2.8 Statistical Analysis 
Student’s unpaired t-test was performed to compare MBV-associated LOX activity 
between MBV and those treated either BAPN or proteinase K. Values are expressed as mean ± 
standard deviation (SD) because one technical replicate was performed for each biological sample 
(n = 3). 
8.3 Results 
8.3.1 BAPN Inhibits MBV-Associated LOX Activity 
β-aminopropionitrile (BAPN) is an irreversible LOX inhibitor [136]. When MBV are 
treated with increasing concentrations of BAPN, the enzymatic activity of MBV-associated LOX 
decreased as measured by colorimetric absorbance (O.D.) (Figure 13A). Significant differences 
are shown beginning from 10 μM of BAPN. In a separate experiment, MBV treated with 50 μM 
of BAPN showed significantly decreased LOX activity measured by fluorescence (RFU) (Figure 
13B). MBV-associated LOX activity is 2-fold greater compared to samples treated with BAPN. 
MBV-associated LOX activity is detectable by both colorimetric (O.D.) and fluorescence (RFU). 
Results in the present study confirm that BAPN inhibits MBV-associated LOX. 
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Figure 13. Inhibition of MBV-associated LOX. (A) MBV-associated LOX activity is significaintly inhibited with 
increasing concentrations of LOX inhibitor β-aminopropionitrile (BAPN). (B) MBV were treated with 50 μM of 
BAPN  and show significant decrease (more than 2-fold) in LOX activity. 
8.3.2 MBV-Associated LOX is Enzymatically Active 
The enzymatic activity of MBV-associated LOX determined. Results showed a significant 
decrease in MBV-associated LOX activity when samples were treated with proteinase K, which 
removes MBV surface proteins, as measured by absorbance (O.D.) (Figure 14). Results suggest 
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that MBV samples treated with proteinase K may not contain as much enzymatic LOX compared 
to those non-treated. MBV-associated LOX is enzymatically active. 
 
Figure 14. MBV-associated LOX is enzymatically active. Enzymatic activity of MBV-associated LOX is 
significantly decreased when treated with proteinase K. 
 
In vitro studies demonstrated the effect of MBV-associated LOX on grown collagen 
constructs. By day 3 after plating, samples with MBV treatment showed constructs that were more 
contracted compared to those left untreated (Figure 15A). The collagen constructs were a linear 
construct. Further morphologic differences were observed at 7 days, where the MBV treated 
samples were defined and compact (opaquer in the middle), whereas the constructs not treated 
were loosely developed (Figure 15B). This suggests MBV-associated LOX has functional activity 
on collagen constructs during development in vitro. In addition, soluble collagen was quantified, 
and those constructs treated with MBV contain the least amount of soluble collagen, suggesting 
those non-treated are less developed (Figure 15C). Histomorphological stain by Masson’s 
Trichrome showed presence of organized collagen (in blue) beginning to develop on the periphery 
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converted to fibrin, which stains in red by Masson’s Trichrome. The presence of collagen in the 
constructs suggests primary tenocytes may be active in remodeling during construct development 
and synthesizing proteins to produce their own ECM. 































Soluble Collagen at 7 days
UBM + BAPN




  63 
Figure 15. (A) MBV-associated LOX influenced the contraction of tendon constructs at day 3 of culture. (B) At 7 
days, morphological difference between samples were clear. MBV treated samples were defined and compact 
whereas the tendons not treated were loosely developed. This suggests MBV-associated LOX has functional activity 
on in vitro collagen constructs during development. (C) Quantification of soluble collagen in collagen constructs. 
Soluble collagen was quantified where those treated with MBV contain the least amount of soluble collagen, 
suggesting those non-treated are less developed.  (D) Histology of constructs composed of tenocytes and fibrinogen 
(red) and the development of organized collagen (in blue) as stained by Masson’s Trichrome. 
8.4 Discussion 
The present study investigates the enzymatic activity of MBV-associated LOX. The role 
of LOX in the cross-linking of collagen and elastin has been studied in multiple tissues including 
skin, lung, and cardiovascular tissues [125-127] and LOX is essential for stabilization of the ECM 
[78, 128-130]. Studies have been limited in fully characterizing LOX and its mechanism due to its 
highly insoluble properties [58]. LOX activity is essential in the formation of covalent bonds 
between collagen molecules and overall stabilization of tissues. Herein, we show that MBV-
associated LOX is enzymatically active and present on the surface of MBV in its pro-peptide form 
when isolated by enzymatic digestion using elastase. 
LOX is synthesized in the cell cytoplasm and glycosylated before entering the Golgi 
apparatus, where it is processed to its inactive 52 kDa pro-peptide from [100]. This pro-peptide is 
secreted in to the extracellular space, where it is cleaved and activated by pro-collagen C 
proteinases (e.g. BMP-1, TLL1, TLL2 [132]) to the 32 kDa enzymatically active form of LOX. 
BMP-1 has been most commonly reported to be involved in the proteolytic processing of the LOX 
precursor to [77, 79, 100]. Although the post-translational processing of LOX was known to be 
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required for enzymatic activity, recent studies reveal otherwise. Specifically, Rosell-Garcia et al. 
reported that the 52 kDa pro-peptide from of LOX  is fully capable of cross-linking collagen [133]. 
The authors also show that cleavage of LOX by BMP-1 or ADAMTS into a "mature" 32 kDa form 
does not increase LOX enzymatic activity, but rather, increases the ability of LOX to bind to 
collagen. In other words, LOX does not need to be cleaved in order to be enzymatically active and 
the proteolytic processing allows for increased binding to different specific substrates. Results 
presented in the present study confirm that the pro-peptide form of LOX is, in fact, enzymatically 
active. 
Numerous studies have shown effective ECM-mediated repair and reconstruction of a 
variety of tissue types, including skeletal muscle, esophagus, dura mater, rotator cuff, and tendon, 
among others. The present study identified the presence of enzymatically active LOX associated 
with MBV, which provides new insights to procedures for isolating LOX. The present study also 
demonstrates MBV-associated LOX activity that affects the growth of collagen constructs in vitro. 
MBV-associated LOX may provide a feasible method to administer LOX as a therapy to enhance 
and strengthen tissues during overuse injuries and diseases such as tendinopathy. Although innate 
healing does occur during tendinopathy alongside degeneration, it results in a mechanically weaker 
tendon formed by scar tissue and collagen fibers with inferior integrity [137]. Therefore, there is a 
significant need for a treatment approach to tendinopathy that can be enacted before complete 
rupture to provide a mechanically strengthened and remodeled tissue. In addition to tendinopathy, 
MBV-associated LOX has therapeutic potential in cases where the tissue strength and integrity is 
weakened, such as large skin grafts, cutaneous wounds, cartilage and ligament repair, and pelvic 
organ prolapse to name a few [12]. MBV-associated LOX may be useful in administering 
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enzymatically active LOX that could support the crosslinking of collagen and enhance the strength 
of tissues. 
The enzymatic activity of MBV-associated LOX was measured and demonstrated in an in 
vitro system for development of collagen constructs. The results show increased formation of 
constructs when treated with MBV. The constructs are made up of primary tenocytes and 
fibrinogen when they are plated. The evidence of collagen in more developed constructs (10 days) 
suggest that the primary tenocytes may be producing their own ECM during development. Further 
studies will determine the mechanical strength of the grown collagen constructs.   
There are many limitations to this study. Although the presence of LOX is valid in our 
results, the use of recombinant LOX as a positive control is still required. The enzymatic of MBV-
associated must be determined in samples isolated by the various solubilization methods as 
described in Chapter 5. In addition, because tenocytes respond to mechanostimulation and are 
sensitive to changes in the mechanical environment, the lack of mechanical stimulation in the in 
vitro system is a limitation. Collagen constructs need further investigation such as quantification 
of insoluble collagen, which suggests more cross-linking, and measurement of mechanical strength 
between the treated and non-treated groups. Future studies will be aimed at further facilitating the 
constructs developed by MBV-associated LOX in vivo for effective site-specific applications of 
tissue strengthening. 
8.5 Conclusions 
Results of the present study show that the 52 kDa form of LOX present on MBV is 
enzymatically active. The findings of this study are consistent with recent reports concerning the 
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proteolytic processing of LOX. Specifically, LOX does not require proteolytic cleavage to be 
enzymatically active. The proteolytic processing ultimately allows for increased binding to 
different specific substrates, such as collagen and elastin in the extracellular space. MBV-
associated LOX promotes the development of collagen constructs in vitro, suggesting faster 
development of mature collagen fibrils. Results from the present study convey MBV-associated 
LOX influences microstructural arrangement of fibers in the matrix by enhancing LOX-mediated 
collagen cross-linking. Implications of this study may guide future in vivo studies that would 
implement MBV as a therapy to strengthen overused and injured tissues. 
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9.0 Tendinopathy and its Degenerative Process: Potential Therapeutic Opportunity for 
MBV-Associated LOX 
9.1 Introduction 
Tendinopathy is one of the most common musculoskeletal diseases that affect both general 
and athletic populations. In the U.S., 33 million patients are affected annually by musculoskeletal 
injuries, of which 50% involve tendons and ligaments [138]. Tendinopathy is an overuse injury 
associated with thickening of the tendon along with chronic pain, inflammation, and tendon 
degeneration [139, 140]. Some of the symptoms of tendinopathy include discomfort, swelling, 
crepitation, and local tenderness. However, tendinopathy can be asymptomatic for a long time until 
it is very advanced. Symptoms vary from patient to patient with inconsistent nature of mild to 
moderate symptoms that often worsen before tendinopathy is diagnosed. Although the affected 
tendon may heal naturally overtime with the natural turnover of collagen fibers, the healed tendon 
is often comprised of a proportion of scar tissue and has inferior mechanical strength compared to 
native, uninjured tendon tissue [141].  
Within the past 50 years, clinical research has guided breakthroughs in orthopedic surgery 
that focus on joint replacements and soft tissue repairs. However, the treatment options available 
for diseases such as tendinopathies and tendon ruptures often leaves both doctor and patient with 
frustrations due to poor healing of the tendon. Surgical techniques and treatment options for 
damaged or diseased tendons are still plagued by complications such as adhesions, loss of strength, 
and possible formation of painful adhesions. Current treatment options for tendinopathy include 
rest, eccentric-concentric exercises, nonsteroidal anti-inflammatory drugs (NSAIDS), and platelet 
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rich plasma (PRP) therapy. However, there is no consensus on the preferred therapeutic option due 
to lack of proven data and insufficient understanding of tendon healing pathophysiology. In the 
case of complete tendon rupture, as in Achilles tendon rupture, surgical repair of the tendon is 
typically required, but it is associated with high morbidity and the possibility of re-rupture of the 
tendon ([13]). Spontaneous complete rupture of a tendon is always due to chronic degenerative 
changes that have started long before the injury. Therefore, there is a significant need for a 
treatment approach to tendinopathy that can be enacted before complete rupture to provide 
a mechanically strengthened and remodeled tissue. The current gold standard for tendon 
reconstruction is tendon suturing, but there is a limit to the amount of tissue that can be harvested 
before compromising the donor site. An ideal graft for tendon engineering and repair would avoid 
donor site morbidity, promote functional constructive remodeling, and have positive histological 
and mechanical results after implantation; all of which have been achieved by utilizing 
decellularized ECM as a biologic scaffold. ECM bioscaffolds facilitate constructive tissue 
remodeling, a process by which the scaffold material degrades with an associated infiltration of 
cells from surrounding tissues and release of bioactive components including matrix-bound 
nanovesicles (MBV).  
The present study utilizes a rat model of collagenase-induced Achilles tendinopathy for 
further determination of the effects of MBV-associated LOX on the tendon healing process.  The 
purpose of this study was to assess whether intra-tendon delivery of an ECM-derived hydrogel or 
MBV would improve the quality and timing of healing in Achilles tendon repair using a rat 
collagenase-induced tendinopathy model. Understanding the degenerative process of tendinopathy 
allows for optimization of timing when MBV-associated LOX can be utilized for cross-linking 
collagen and enhancing the strength of the healed neotendon.  Once a tendinopathy model was 
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established and confirmed, a preliminary study was performed for treating tendinopathy using 
hydrogels and MBV derived from ECM.   
9.2 Materials and Methods 
9.2.1 Experimental Design Overview 
The goals of this study were to 1) establish and confirm a rat Achilles tendinopathy model 
and 2) investigate the use of ECM-derived hydrogels and MBV as a non-invasive approach to treat 
tendinopathy. The study design is shown in Figure 1. Forty-eight Sprague Dawley rats received 
collagenase injections in the Achilles tendon to induce tendinopathy. The degenerative process of 
the tendon was observed at 3, 7, 10, 14, 28, 56, 84, and 112 days and rats were divided for 
histomorphological assessment (n = 4 at each timepoint) and uniaxial mechanical testing (n = 2 at 
each timepoint) (Fig. 16, blue arrows). An additional study was performed where ECM hydrogels 
and MBV were used as treatments 14 days after the collagenase injection (Fig. 16, orange arrows). 
For this study, the effect of treatments was observed at 1 week and 6 weeks after treatments. 
Animals were divided for histomorphological assessment (n = 3 at each timepoint) and uniaxial 
mechanical testing (n = 3 at each timepoint).   
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Figure 16. Experimental Design Overview. Tendinopathy is induced by injection of collagenase. The degeneration 
process of the tendon was observed at 3, 7, 10, 14, 28, 56, 84, and 112 days followed by histomophological 
assessment and uniaxial mechanical testing (blue arrows). In another study, tendionpathy was treated using ECM-
derived hydrogels and MBV after 14 days of collagenase injection (orange arrows). Experimental analyses 
included histomopholic assessment and uniaxial mechanical testing at 1 week and 6 weeks post treatments.  
9.2.2 Achilles Tendinopathy Rat Model 
To induce tendinopathy, a single incision was made in the superficial tissues overlying the 
right Achilles tendon to expose the tendon tissue (Figure 17A) and 60 μl of 5 mg/ml collagenase 
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from clostridium histolyticum (Sigma, C0130) was injected (Figure 17B). The contralateral left 
tendons were left untreated to serve as controls.  Tendon degeneration was observed for 3, 7, 10, 
14, 28, 56, 84, and 112 days. Analyses included histomorphological assessment and uniaxial 
tensile mechanical testing of tendons.  
 
Figure 17. Achilles tendinopathy rat model. (A) A single incision is made to expose the tendon, grasped with 
curved hemostat in the figure. (B) 60 μl of 5 mg/mL of collagenase from clostridium histolyticum is injected into the 
tendon to induce tendinopathy 
9.2.3 Preparation of Tendon ECM (tECM)  
Achilles tendons were harvested from domestic pics (50-54 kg) and the tendon sheath and 
paratenon were removed. Tendons were cut into 1x1 cm pieces and pounded into approximately 2 
mm thickness with a heavy mallet. The tissues were subjected to 5 freeze-thaw cycles in deionized 
water by using liquid nitrogen. Subsequently, tissues were washed 3 times in 4% Triton X-100 
(Sigma Aldrich, St. Louis, MO) on an orbital shaker for 20 minutes at room temperature, and 
incubated in deionized water overnight at 37°C on an orbital shaker at 300 rpm. After the 
incubation, tendons were washed in PBS (Fisher Scientific) for 30 minutes 4 times, 0.1% peracetic 
acid (Rochester Midland Corp., Rochester, NY) in 4% ethanol for 2 hours, PBS for 15 minutes, 
A B
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Type I H2O for 15 minutes 2 times, and a final PBS wash for 15 minutes. All washes were 
performed at room temperature with agitation on an orbital shaker at 300 rpm unless otherwise 
stated. Finally, tissues were frozen and lyophilized for future experiments. Tendon ECM (tECM) 
met stringent requirements for sufficient decellularization; specifically, no visible intact nuclei by 
DAPI and hematoxylin and eosin (H&E) staining, remnant DNA concentration less than 50 ng/mg 
total dry weight of ECM, and DNA fragment length less than 300 base pairs. 
9.2.4 Preparation of ECM Hydrogels 
Urinary bladder matrix (UBM) [108] and tendon ECM (tECM) were prepared as described 
previously. ECM hydrogels were then prepared using lyophilized and powdered UBM and tECM 
as described previously [142]. Briefly, powdered ECM (10 mg/ml) was digested with pepsin in 
0.01 M HCl at room temperature with a constant stir for 48 hours, and stored at -20°C. Hydrogels 
were thawed right before use as treatments, and neutralized (pH = 7.4) with 0.1 M NaOH and 
diluted to the final concentration of 8 mg/ml.  
9.2.5 Isolation of MBV 
Matrix-bound nanovesicles (MBV) were isolated from UBM as described previously [41]. 
Briefly, lyophilized and powdered UBM ECM (10 mg dry weight) was enzymatically digested by 
collagenase (0.1 mg/ml) in buffer [50 mM Tris (pH = 8), 5 mM CaCl2, 200 mM NaCl] for 24 hours 
at room temperature. Enzymatically digested ECM was then subjected to successive centrifugation 
at 10,000 xg for 30 min and the supernatant was passed through a a 0.22 m filter (Millipore). The 
clarified supernatant was then centrifuged at 100,000 xg (Beckman Coulter Optima L-90K 
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Ultracentrifuge) at 4C for 70 min. The MBV pellet was then resuspended in 100 l of 1X sterile 
PBS. 
9.2.6 Treatment of Achilles Tendinopathy  
Fourteen days post-injection of collagenase, tendons were treated with either UBM 
hydrogel, tECM hydrogel, MBV isolated from UBM, or saline as a control. Neutralized hydrogels 
and MBV were kept on ice. 50 l of each respective treatment was then injected directly into the 
injured tendon.  
9.2.7 Necropsy 
Animals were sacrificed by CO2 inhalation and cervical dislocation at their pre-determined 
timepoint for both studies. Samples that were harvested which included the calcaneus, Achilles 
tendon, and gastrocnemius muscle tissues. Samples for histology were fixed in 10% neutral 
buffered formalin (NBF) while samples for mechanical testing were wrapped in gauze soaked in 
PBS and kept on ice. Uniaxial tensile mechanical testing was performed immediately after tissue 
harvest.  
Samples for histology were fixed in NBF for at least 7 days. Samples were then embedded 
in paraffin, cut into 5 m longitudinal sections, and mounted onto glass slides for H&E staining.  
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9.2.8 Uniaxial Tensile Mechanical Testing 
Immediately after tissue harvest, uniaxial tensile mechanical testing was performed using 
the Instron 3340 series mechanical testing systems (MTS® Eden Prairie, MN). Harvested tendons 
were clamped at proximal and distal ends with serrated-jaw metal grips (Figure 18). Sandpaper 
was placed between the tissue and grips to prevent slippage. The resulting load was measured 
using a 100 N load cell. A uniaxial tensile ramp-to-failure was applied at a strain rate of 0.1%/s 
and the resultant load was recorded. Samples were tested to failure, which was indicated by 
complete tear of tendons. The stress-strain curve was analyzed to determine ultimate peak stress.  
 
 
Figure 18. Harvested tendons were held at proximal and distal ends 1 cm apart by serrated-jaw metal grips. 
Sandpaper was placed between the tissue and grips to prevent slippage. 
9.2.9 Scanning Electron Microscopy (SEM) 
Native porcine Achilles tendons were processed for SEM. Briefly, samples were harvested 
and rinsed in 1X PBS before fixing in 2.5% glutaraldehyde in 0.1 M PBS (pH = 7.4) for 10 minutes. 
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The tissues were cut into small blocks (8 mm³) and were washed thoroughly in three changes of 
0.1 M PBS for 15 minutes each.  Samples were dehydrated in a graded serious of ethanol in PBS 
including 30%, 50%, 70%, 90% for 15 minutes each. Samples were than dehydrated in 100% for 
15 minutes three times. Samples were mounted on sputter coated with 3.5 nm of gold/palladium 
alloy.    
9.2.10 Statistical Analysis 
A two-way ANOVA and Fisher’s least significant difference (LSD) post-hoc analysis was 
used to compare the independent variables treatment and timepoints. For statistical analysis, 
significance was set at p < 0.05. Error bars represent standard deviation. 
9.3 Results 
9.3.1 Histological Assessment of Degenerating Tendons 
Achilles tendons were evaluated by histomorphological assessment. Representative images 
are shown of tendon tissue sections stained with H&E at each timepoint (Figure 19A). At 3 days, 
robust inflammatory cellular infiltration is present, with a mixture of neutrophils and mononuclear 
cells. At 7 days, there is more dense cellular infiltration compared to 2 days, with large nuclear 
bundles and areas of degeneration. At 10 days, there is a decrease in mononuclear cells and 
regression of vascularity. At 14 days, there are a mix of aligned and not aligned fibroblast cells 
with almost no inflammatory cells present. At 28 days, there are areas of regenerating tendon with 
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increased cellularity. There appears to be new matrix production and proliferation of fibroblasts. 
At 56 days, there are similar histologic findings with signs of a healing tendon and aligned 
fibroblasts indicating maturation. At 84 days, there were signs of chondrogenesis without the 
presence of inflammatory cells. Finally, at 112 days, there are highly aligned mature collagen 
fibers but a lack of uniform cell alignment. Gross morphology of the tendons is shown in Figure 
19B, where tendons with collagenase-induced degeneration show relative thickening and 
irregularity over the course of the disease process. 
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Figure 19. Histomorphological assessment and gross images of tendons. 
9.3.2 Uniaxial Tensile Strength of Degenerating Tendons  
The mechanical strength of tendons injected with collagenase were not statistically 
significant compared to normal tendons. Although few tendons exhibit high values of peak stress 
until ultimate failure, the individual datapoints were not reproducible for statistical significance 
(Figure 20). Tendons harvested at 56 days had experimental errors of tissue slippage from the 
metal grips, resulting in damage to the tissues that prevented further data collection on these 
samples. 
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9.3.3 Achilles tendinopathy is Induced at 14 Days Post-Collagenase Injection 
Collagenase was injected to induce tendinopathy in rat Achilles tendons. Histological 
assessment verified an inducible tendinopathy model that compares favorably to tendinopathy in 
humans, which is characterized by cellular infiltration and inflammation in the tendon tissue 
(Figure 21).  
 
Figure 21. Tendinopathy induced in rat model. At 14 days, histology verified an inducible tendinopathy model 
that compares favorably to tendinopathy in humans that is characterized by cellular infiltration and inflammation in 
the tendon. 
9.3.4 ECM Hydrogels and MBV Affect Achilles Tendinopathy 
Treatments including UBM hydrogel, tECM hydrogel, MBV, and saline (control) were 
applied to injured tendons after 14 days of induced tendinopathy. At the 1 week timepoint, 
histomorphological assessment by H&E staining showed cellular infiltration and 
neovascularization at the level expected for healing response in normally poorly vascularized 
tissues such as the tendon [143]. Cellular response was greater at the 1 week timepoint compared 
to 6 weeks (Figure 22). At the 6 week time point, the relative healing response of the tendon is 
Collagenase-induced rat 
tendinopathy 
Human patient with 
tendinopathy
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most notable in the ECM hydrogel and MBV treatment groups compared to the saline (control) 
group.  
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Figure 22. Tendons were harvested and processed for histology by hematoxylin and eosin (H&E) staining. 
Evidence of cellular infiltration and neovascularization corresponds to the healing response in normally poorly 
vascularized tissues such as the tendon. At the 1 week time point, there is a more robust cellular response than at 6 
weeks. At the 6 week time point, the relative healing response is most notable in the ECM treatment and MBV 
groups compared to the saline (control) group. 
 
Results from uniaxial mechanical tensile testing on treated tendons showed promising 
trends between the treatment groups (Figure 23). Although the data was not statistically significant, 
peak stress values between the treatment groups suggest there was an effect on the tendon 
remodeling process. 
 
Figure 23. Comparison of mean peak stress values of rat tendons at 1 week and 6 weeks with standard error. 
Though results are not statistically significant, there are promising trends between the treatment groups with respect 
to the peak stress values as the tendon was remodeling. 
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9.4 Discussion 
The term “tendinopathy” is used as an umbrella term to describe a painful condition of the 
tendon [141]. Although “tendinopathy” can describe any diseased or disordered tendon tissue, it 
includes complex processes that involve changes in biological structure, composition, and 
mechanics. In tendinopathic tissues , there are degenerative changes in the extracellular matrix 
(ECM) [144]. In the presence of tendinopathy, the healing response is defective due to accumulated 
micro-injuries from overuse and the tendon tissue is unable to repair effectively. The present study 
investigates the effect of ECM-derived hydrogels and matrix-bound nanovesicles (MBV) as 
treatments in a rat Achilles tendinopathy model. These treatments provide a novel, non-invasive 
regenerative medicine-based approach to treat an acute Achilles tendon injury by using an 
injectable ECM-based material. Hydrogels have been gaining popularity as a delivery vehicle of 
cells, growth factors, and other bioactive molecules [145]. In addition, MBV have been described 
as bioactive components of ECM and have been shown to recapitulate the biologic effects of the 
parent ECM [41].  
Although the Achilles tendon is the largest and strongest tendinous tissue in the body, it is 
subjected to substantial loads of that frequently cause microtears and overuse injuries. Overuse 
injuries have been a perpetual orthopedic problem and the recurrence of these injuries begins 
during exertion as the tendon is subjected to repetitive tissue microtrauma [146]. Repetitive 
microtrauma results in microscopic injuries that are notoriously known to not be diagnosed until 
the injuries have worsened. Repetitive use and activity may eventually lead to cumulative 
microtrauma that weakens collagen cross-linking, non-collagenous matrix, and vascular elements 
of the tendon tissue [147]. Tendon pathology is often the result of overuse and strain that causes 
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an accumulation of the aforementioned tendon microtears without sufficient time for complete 
healing and matrix turnover [139, 148].  
The field of orthopaedic surgery has experienced incredible advancements since its 
inception from historical wartimes to progressive developments in the last 50 years. Clinical 
research has guided significant breakthroughs in orthopedic surgeries that focus on joint 
replacements and soft tissue repairs [149, 150]. However, the treatment options available for 
diseases such as tendinopathies and tendon ruptures still require invasive surgeries that often result 
in patient discomfort and restricted foot movement. Despite advancements in orthopedic surgical 
techniques and technologies, the incomplete knowledge and understanding of the mechanisms 
steering tendinopathy prevents the development of better therapies. One of treatment strategies for 
musculoskeletal injuries has been the administration of platelet rich plasma (PRP) to stimulate 
regeneration of the injured tissue [151-153]. Despite published studies reporting success with PRP 
treatment, the data is not sufficient to consider it as the treatment of choice. PRP treatment also 
has batch-to-batch variability and concentration variation. Additionally, it requires blood from the 
patient, which could ideally be avoided with alternate therapies. Furhter, the potential of PRP 
depends on the donor, so obtaining blood from older patients for use as PRP is questionable. 
Ultimately, the current available treatment options have the disadvantage of providing insufficient 
repair of the injured tendon. Even with PRP and/or stem cells, the enhancement of healing is not 
sufficient, and the field of orthopedic surgery needs more effective treatment options. Thus, there 
is a need for a non-invasive approach for treating tendinopathy that promotes the regenerative 
process of the injured tendon. An ECM-based material such as bioscaffold or MBV would be a 
great treatment option. 
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Acellular ECM biologic scaffolds have been used to provide a compatible and instructive 
template for endogenous cell infiltration and differentiation that provide a supportive 
microenvironment that promotes a constructive remodeling response. In addition, hydrogels 
derived from components of the ECM (e.g., collagen, hyaluronic acid, and elastin) have been 
implemented in numerous studies and clinical applications. Herein, the use of hydrogels derived 
from decellularized mammalian tissue is investigated to implement the advantages of using ECM 
as a bioscaffold in regenerative medicine. ECM hydrogels have the advantage of retaining the full 
biochemical complexity of native tissue as compared to hydrogels composed of only individual 
ECM components.  Hydrogels derived from UBM, which contain the milieu of bioactive ECM 
components, have been shown to retain the inherent bioactivity of the native matrix with the ability 
to promote constructive remodeling in heterologous tissue applications [142, 154, 155].  
By augmenting the natural healing process of an injured tissue, ECM-derived materials 
such as hydrogels and MBV provide an inductive template that recapitulate the appropriate 
microenvironmental niche for host cell infiltration and differentiation. Although the results from 
the present study do not reach statistical significance, they provide important insights into the 
therapeutic potential of ECM to reinforce the regenerative process of the injured tendons as they 
heal. 
9.5 Conclusions and Limitations 
Herein, the therapeutic effect of ECM-derived hydrogels and MBV isolated from ECM 
were studied in an in vivo rat Achilles tendinopathy model. The results of this study show that 
treatment of a collagenase-induced tendinopathy with ECM hydrogel and MBV in a rat model 
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induces a robust healing response, including cellular infiltration and neovascularization, when 
compared treated with saline alone. The ECM hydrogel and MBV treatments provide a potential 
non-invasive method promoting restoration of tendon mechanical strength and collagen cross-
linking.  Future work will include isolated PRP as an experimental group in a head-to-head trial 
with currently available treatment options.  
There were multiple limitations to the study. The uniaxial mechanical tensile testing of rat 
Achilles tendons included challenges with tissue mounting and reliable fixation to the metal grips 
at each end of the tendon tissue. Tendons often slipped from the grips, which ultimately impacted 
the quality of the tissues being tested. In addition, MBV were isolated by enzymatic digestion of 
collagenase. While the isolation process of MBV aims to eliminate all collagenase used the 
digesting the ECM, any contamination of MBV with residual collagenase could impact and 
potentially negate the positive impacts of MBV on tendon healing and strengthening. Future work 
will include MBV isolated by elastase digestion, where lysyl oxidase (LOX) would remain 
associated to the surface of MBV to regulate cross-linking of collagen in the tissue. The therapeutic 
potential of applying MBV-associated LOX is overall an attractive tool for enhancing the 
biomechanical properties of injured tissue. 
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10.0 Dissertation Summary and Future Perspectives 
The work presented in this dissertation identified and investigated an extracellular source 
of lysyl oxidase (LOX), specifically associated to matrix-bound nanovesicles (MBV). The central 
hypothesis addressed in this work is that MBV are an extracellular source of LOX and can be used 
to implement the enzymatic function of LOX in regulation of collagen and the ECM. Major 
findings for each specific aim are summarized below. 
 
Specific Aim 1: Identification and characterization of LOX isoforms in MBV isolated from ECM 
bioscaffolds 
Summary of major findings: MBV-associated LOX was isolated from urinary bladder 
matrix ECM (UBM-ECM), small intestinal submucosa ECM (SIS-ECM), dermal ECM (dECM), 
and tendon ECM (tECM). For this work, the process of tECM preparation was developed and 
optimized. The effect of different ECM solubilization methods prior to isolating MBV by 
ultracentrifugation was investigated. These solubilization methods included enzymatic digestion 
with elastase and collagenase or incubation in a high salt (NaCl) solution. MBV-associated LOX 
was identified to be present on the surface of MBV when elastase was used to enzymatically digest 
ECM. These results persisted in vesicles that were isolated from native porcine tissues that were 
not processed by decellularization. When solubilization was carried out with collagenase or NaCl 
solution, MBV-associated LOX was degraded or eluted off the vesicles. These results suggest that 
MBV-associated LOX is bound to other lipid-membrane proteins, which were either disrupted by 
the non-specific activity of collagenase or dissociated by the high NaCl solution.  
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In our previous studies, enzymatic digestion of ECM by collagenase was utilized  to digest 
the ECM before isolating MBV by ultracentrifugation [41, 56]. The findings of Specific Aim 1 
provide insights on how MBV are firmly embedded in the ECM and how different solubilization 
methods of ECM can affect the presence MBV surface proteins like LOX.  
Future perspectives: LOX plays an integral role in ECM remodeling and ultimately 
determines the extent of intermolecular cross-linking between collagens and elastin. The presence 
of LOX associated to the surface of MBV reveals more information about how MBV are integrated 
within the matrix and how they function differently than extracellular vesicles found in biological 
fluids. The challenges associated with isolation and purification of LOX have limited studies 
investigating LOX and its specific mechanisms in normal physiology, fibrosis, and cancer 
metastasis. The discovery of LOX as a surface protein of MBV provides new insights to a possible 
alternative pathway LOX is secreted into the extracellular space.  
The varying amount of MBV-associated LOX identified in various ECM sources in 
varying amounts suggests the functional role LOX plays in specific tissues. In addition, successful 
isolation of MBV directly from native porcine tissues is evidence that decellularization of tissues 
is not required prior to the isolation of MBV. Although the decellularization process for ECM 
biologic scaffolds is important to avoid detrimental immune responses, it is plausible that 
decellularization of source tissues may not be required prior to isolation of MBV that is ultimately 
intended for therapeutic purposes. This would greatly streamline the process of isolating MBV, 
potentially improving the time and cost associated with implementing MBV-associated LOX in 
clinical applications. Future work should determine if MBV isolated from native tissues has the 
same biologic effect compared to MBV isolated from decellularized ECM. 
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For additional future work, the effects of other solubilization and isolation methods to 
isolate MBV-associated LOX should be investigated. For example, solubilization of ECM with 
pepsin and isolation of MBV-associated LOX size-exclusion chromatography (SEC) have not been 
explored. Pepsin has been utilized to solubilize ECM for preparation of hydrogels [156], and has 
been shown to partially digest the ECM compared to proteinase K [41]. This would offer a more 
specific or gentle method of solubilization, potentially resulting in the retention of more MBV-
associated LOX or other MBV surface proteins. The use of SEC to isolate MBV may also provide 
higher yield and purity of vesicles compared to those isolated by ultracentrifugation [157].  These 
isolation methods may affect the presence of other LOX isoforms associated to MBV, which could 
be explored by Western blot analysis or furthered by liquid chromatography-tandem mass 
spectrometry (LC/MS) for global proteomics.  
   
Specific Aim 2: Determine the biologic activity of MBV-associated LOX  
Summary of major findings: MBV-associated LOX was identified in its 52 kDa pro-
peptide form when isolated by using elastase digestion before ultracentrifugation. Although LOX 
is previously known to require extracellular processing by pro-collagen proteinases for enzymatic 
activity, MBV-associated LOX is enzymatically active. The enzymatic activity of MBV-
associated LOX is inhibited by treatment with BAPN. In addition, MBV-associated LOX activity 
significantly decreases when treated with proteinase K. The mechanism of LOX’s association to 
the MBV surface was suggested by the distinctly different protein signatures of MBV-associated 
LOX with and without treatment of proteinase K. Specifically, the absence of LOX on the surface 
of MBV following proteinase K treatment suggests a possible membrane-bound protein partner. 
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However, more work is needed to confirm that proteinase K did not simply disrupt LOX that was 
interacting directly with the MBV lipid membrane. 
Future perspectives: Of the LOX isoforms, LOX and LOXL1 have similar pro-domains 
that require cleavage for their activation. However, recent studies have reported that the proteolytic 
processing of LOX allows for substrate specificity and binding for cross-linking [133]. This 
information may be relevant to MBV-associated LOX, which in the present dissertation was 
determined to be enzymatically active. The presence of LOX bound to the surface of MBV 
suggests an alternative pathway of LOX secretion, where the pro-peptide LOX piggybacks along 
with MBV into the extracellular space. Then, proteolytic processing may occur by pro-collagen 
proteinases to cleave MBV-associated LOX for proteolytic processing and specific substrate 
binding. 
There is evidence in literature identifying ECM proteins interacting with LOX that may be 
important in the extracellular proteolytic processing of the pro-peptide LOX. Fogelgren et al. 
reported cellular fibronectin, as well as tropoelastin and collagen, interacting with LOX in 
glutathione S-transferase pull-down and solid phase binding assays [78]. Maruhashi et al. reported 
the interaction of periostin with BMP-1, which enhanced the deposition of BMP-1 in the ECM, 
and resulted in proteolytic cleavage of LOX [79].  Sasaki et al. reported that the proteolytic 
processing of LOX is decreased in fibulin-4 deficient osteoblasts and rescued when recombinant 
fibulin-4 was added, suggesting the importance of fibulin-4 for LOX’s enzymatic role to cross-
link collagen and elastin [158]. Thrombospondin-1 has also been identified to bind to collagen and 
inhibit the processing of LOX by BMP-1 [159]. The evidence of LOX’s interaction with various 
substrates maybe applicable to MBV-associated LOX and its biological role in the matrix. It is 
plausible that there are even subpopulations of MBV that do not have LOX associated to its surface. 
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LOX that is associated to MBV may represent a directed mechanism in which the cell releases 
MBV-associated LOX for cross-linking of specific substrates in the extracellular space. 
Although studies provide insight to extracellular proteins interacting with LOX, the lipid-
membrane associated partners of LOX bound to the surface of MBV remains unknown. MBV 
remain structurally intact even after the decellularization process and isolation from ECM [41]. 
Thus, the identified LOX protein with MBV is clearly associated to the outer surface rather than 
the lumen of MBV.  The findings of Specific Aim 2 may provide better understanding to MBV’s 
constituent phospholipid profiles, which has been shown to be distinctly different to extracellular 
vesicles in biologic fluids (i.e., exosomes) [53]. This has important implications for the use of 
MBV as a therapeutic similar to the use of exosomes for diagnostic purposes [160].  
Future experiments should determine the enzymatic activity of MBV-associated LOX in 
MBV isolated by various solubilization methods as described in Chapter 5. Determining if the 
proteolytically processed MBV-associated LOX is enzymatically active would provide further 
insight into the enzymatic mechanism of LOX. In addition, the effect of specific substrates binding 
with MBV-associated LOX should be investigated. It is plausible that the enzymatic activity of 
MBV-associated LOX is increased when bound to fibronectin. Alternatively, a bound substrate 
may serve to protect the pro-peptide of LOX and decreases its activity. Future work is needed to 
further investigate the biologic role of MBV-associated LOX. 
 
Specific Aim 3: Determine the effect of MBV isolated ECM on the mechanical properties of a 
grown collagen construct in vitro by measurement of mechanical strength 
Summary of major findings: MBV-associated LOX isolated from UBM showed biological 
and functional activity on collagen constructs during development in vitro. The isolation of 
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primary tenocytes from rat tails and the collagen construct in vitro system were optimized for the 
study. Constructs that were treated with MBV showed clear morphological differences compared 
to those left untreated. Specifically, MBV treated constructs were defined and compact whereas 
those not treated were loosely developed. In addition, the development of constructs was enhanced 
by the treatment of MBV and constructs contracted more quickly in a linear form. Histologically, 
treated constructs grown out to 10 days showed the development of collagen in the periphery of 
the constructs. This suggests MBV-associated LOX has functional activity on in vitro tendon 
mimics during development.   
Future perspectives: LOX has been identified to play important roles during tissue 
development and organogenesis [161, 162]. The ability of LOX to modulate the cross-linking of 
collagen and subsequent deposition of the ECM gives great potential for MBV-associated LOX to 
have such effects. MBV-associated LOX has biologic effects on the development of collagen 
constructs in vitro, suggesting its ability to modulate the main constituents of ECM. Biomaterials 
composed of ECM have successfully been used as surgical meshes, powders, and hydrogels in a 
variety of surgical applications for tissue engineering and regeneration. Many types of ECM are 
also FDA-approved and can be preserved to be used as an “off-the-self” product [163, 164].  
UBM-ECM is commercially available (MicroMatrix®, ACell) and one of the main ECM 
types that was used to investigate MBV-associated LOX in the present dissertation. With further 
testing and investigation, MBV-associated LOX has great potential to become a readily available 
commercialized product to strengthen tissues. Future experiments would include additional in vitro 
studies that would be used for further analyses. Such analyses would include MBV treated with 
LOX inhibitor BAPN, MBV isolated from various ECM bioscaffolds, and MBV isolated by 
various methods of solubilizing ECM. Further understanding of the development of collagen 
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constructs can be investigated by the use of qRT-PCR characterization of the expression of genes 
that are associated with the ECM (e.g., collagen, elastin, fibrin, MMPs). In addition, testing the 
mechanical strength of the grown tendon constructs would be performed.  
An ideal collagen construct would have an increased mechanical strength and collagen 
fibril organization when MBV-associated LOX is administered. Further, the deposition of collagen 
present in the construct should be enhanced in the presence of MBV-associated LOX.   These 
characteristics of an ideal construct may be better achieved in vitro if grown in an environment 
where constant or intermittent mechanical stimulation is included. Studies have shown the 
importance of mechanical cues and mechanical loading during development of embryonic tendons 
[6, 165]. The addition of mechanical stimulation may enhance the functional properties of the 
developing construct that may be implemented alongside treatment with MBV-associated LOX.  
The findings of Specific Aim 3 provide insight to the effects MBV-associated LOX on in 
vitro development of collagen constructs. In order to further understand the role of MBV-
associated LOX, efforts should focus on how MBV-associated LOX influences cross-linking of 
collagen and how this cross-linking affects the strength and mechanical properties of ECM. The 
work in the present dissertation and future studies can together provide a functional application for 
MBV-associated LOX that can be implemented in tissue engineering design of biologics to 
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